

Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use (II)

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10 Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonnier et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30 The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendotherial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or

5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological

10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems.

15 Targeting or modulation of the biological activities of VEGF/VEGF receptor systems and of Angiopoietin/Tie receptor systems can be performed by

(a) compounds which inhibit receptor tyrosine kinase activity,

(b) compounds which inhibit ligand binding to receptors,

(c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,

(d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,

(e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

(f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30 A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca:


5 ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is
10 prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin
15 A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhUMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas
20 (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.
Receptor blocking antibodies have been described by Imclone (c-p1C11, US
25 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

30

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

- 10 Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I




in which

r has the meaning of 0 to 2,
n has the meaning of 0 to 2;


R₃ und R₄ a) each independently from each other have the meaning of lower alkyl,

b) together form a bridge of general partial formula II,



wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

c) together form a bridge of partial formula III



wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,
 R₁ and R₂ independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

5 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated
 10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
 15 more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenese, respectively, which results in a prevention of tumor growth and tumor spread, are for example

anthranyl acid derivatives of general formula IV

30



in which

A


has the meaning of group $=NR^2$,

W


has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$, $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the group



or A, Z and R^1 together form the group



m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/or R_a and/or R_b together with R_c and/or R_d or R_c together with R_e and/or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

has the meaning of group =NR⁹ or =N-,

has the meaning of group -(CH₂)_p,

has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,


independently from each other have the meaning of hydrogen, halogen or C₁₋₆-alkoxy, C₁₋₆-alkyl or

R²

R³

R⁴, R⁵, R⁶ and R⁷

C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group




5 R⁸, R⁹ and R¹⁰

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.

10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V



15


V,



in which

R¹





has the meaning of group

20








in which R^5 is chloro, bromo or the group $-OCH_3$,



in which R^7 is $-CH_3$ or chloro,



in which R^8 is $-CH_3$, fluoro, chloro or $-CF_3$




in which R^4 is fluoro, chloro, bromo, $-CF_3$, $-N=C$, $-CH_3$, $-OCF_3$ or $-CH_2OH$

in which R^6 is $-CH_3$ or chloro

R^2

has the meaning of pyridyl or the group



and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases. Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-

- 10 pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred
15 pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical
20 compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

- The small molecule compounds, proteins and DNA's expressing proteins, as
25 mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome,
30 transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch.

The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with
- 5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
- 10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
- 25 tyrosine kinases Tie1 and Tie2.

- Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
- 30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, .
angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma,
kidney diseases, such as glomerulonephritis, diabetic nephropathie, maligneous
nephrosclerosis, thrombic microangiopatic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell
proliferative diseases, artherosclerosis, damage of nerve tissues, suppression of
the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector

15

(A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-

20

phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
- 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv)

specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing

10 recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx.

200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of

treatment are described in Table 3. Animals were sacrificed for ethical reasons

15 when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-B domain of fibronectin and the extracellular domain of tissue factor was expressed in *E. coli* as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm³, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days.

10

Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

15

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF-receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPM1XX00-P

15

<140>

<141>

<160> 59

20

<210> 1

<211> 1835

<212> DNA

<213> Human

25

<400> 1

30

```

ttttacagtt ttccttttct tcagagttta ttttgaattt tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt tttttttaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaaca gccaaaaaac cataatggtg ccacagggat ggagcagggg agggcatctc 300
taacgtgtcc tctagtctat ctctgctaaa cagaacccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420
aagcaaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaaggc ttggatggtta agagaggaca ctacagcggt cctgaaggga gacgctgaga 660
tggaccgctg agaagcggaa cagatgaaca caaaggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccacaaacgca acctaaccac agcaaaatct 780
aagcaaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgctac gtgccaacct aagtctctca cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcggtta gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatag 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc agggggcgaca 1080
tccgccaaag tcctccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac ggtacgcgc ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcaggtgggt ctgcatagc tcatttaatg ttaaaccgca tcaggggcct ctccctccgt 1320
ttctgccagg ggcttttctt gtcttctcct tggcagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat ccgcagtcg tctggtcgtc tctctctgca 1440
ggctgggcag ctggccacca cttctccgac tcgacccctc caacaagcat cgaggggcac 1500
tgtcctcggg ggtacagacc gtggtccac attcgtacc actctgttcc acgtcatcca 1560
ggtacacgag ctgctgttag gccgtgctgt ctggggctcg aggcctcttc tgetggtgct 1620
cttggacggg cgggtagtct tgctgcagag acaaacgcat tccccttccc ttccgggctg 1680
atcttggttc attcatatct acgcagagt ccaaactggc atcattactt ccgttccttc 1740
cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800
gagacgaacc acgcccggg gtgcggaagc ggcct

```

60

<210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct ctttagaccc ctggggcctg tgctacccag 60
 acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
 tcaacttact tctgtggcc cattagggaa gtggtgacct cgggagctat ttgcctgttg 180
 agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
 tggcccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
 10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
 agttatagtt catacacagt tgattttccat ttataaaggc agaaagtcct tgttttctct 420
 aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggccct 540
 cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3
 <211> 516
 <212> DNA
 <213> Human

<400> 3

tagagatggt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
 tcagcccaga catgtgcatc tacatcacag aggacatgct catgtcgcgg aacctgaatg 120
 25 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
 tcctgcgcac tgcaggctctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
 atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcatcaaca 420
 30 tccaagatgc ttttccagtc aaaagaacca gcaaataactt ttctctggat ctcaactcatg 480
 atgaagttcc agagtttgtt gtgtaaagtc cgtctg

<210> 4
 <211> 1099
 <212> DNA
 35 <213> Human

<400> 4

cccacaacac agggggcctg aaacacgcca gcctctctc tgtggtcagc ttggcccagt 60
 40 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
 ccacggggag gtagaagaag acctggtccg tgtaagggc tgagaagggt ccttgggtcg 180
 ggggtgcgct ttggccttgc cgtgccctca tccccgggt gaggcagcga cacagcaggt 240
 gcaccaactc cagcaggtta agcaccagg agatgagtc aaccaccaac atgaagatga 300
 45 tgaagatggt cttctccgtg gggcgagaga caaagcagtc cacgaggtag gggcaggggtg 360
 ctgcgtggca cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420
 ggaagcctgc ctctagcaca ctcttgacga gcacactggc gacataggtg cccatcagtg 480
 ctccgcggat gcgcaggcga ccattctctg ccaccgagat cttggccatc tgacgctcta 540
 cgcccgccag cgcccgctcc acctgtgggt ccttggccgg cagtgcgccg agctccccct 600
 50 ccttctgccg cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660
 ggggtgggtg gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720
 aggccctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
 actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840
 agagcaccgt cagccagatc ttaccaccca cggtcgagtg ctcttgacc tgggtccagca 900
 55 acttctccac gaagccccag tcacccatgg ctccccggcc tccgtcggca aggagacaga 960
 gcacgtcag gtgtcagcat ggcattcttc tcgttcgccc agcaacaagc ctgcagggag 1020
 gtctgccacg cccgttctac cgcctgcctg ccgggcggcc caggtggagg tggggacgat 1080
 ggccggagtg acgcccgcg

60 <210> 5
 <211> 1015
 <212> DNA
 <213> Human

<400> 5

65 gaggataggg agcctggggg caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

5 aaaaagtgct ttttgaaaat gttgaggttg aaatgatggg aaccaacatt ctttggattt 120
 agtgggggagc ataatagcaa acaccccctt ggttcgcaca tgtacaggaa tgggacccag 180
 ttgggggcaca gccatggact tccccgcctt ggaatgtgtg gtgcaaagtg gggccagggc 240
 ccagacccaa gaggagaggg tgggtccgcag acaccccggg atgtcagcat cccccgacct 300
 gccttctggc ggcacctccc ggggtgctgtg ttgagtcagc aggcattggg tgagagcctg 360
 gtatatgtctg ggaacagggt gcagggggcca agcgttcctc cttcagcctt gacttggggc 420
 atgcaccccc tctcccccaa acacaaacaa gcacttctcc agtatgggtg caggacagg 480
 gtcccttcag tcctctgggt atgacctcaa gtcctacttg ggcctgcag cccagcctgt 540
 gttgtaacct ctgcgtcctc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600
 10 atcatcattg ttgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660
 aatgtgcttc cctccctggg gtctcacacg ctcccacgag aatgccacag gggccgtgca 720
 ctgggcaggc ttctctgtag aaccccaggg gcttcggccc agaccacagc gtcttgccct 780
 gagcctagag cagggagtc cgaacttctg cattcacaga ccacctccac aattgttata 840
 accaaaggcc tcctgttctg ttatttctact taaatcaaca tgctattttg ttttctactca 900
 15 cttctgactt tagcctcgtg ctgagccgtg tatccatgca gtcattgttca cgtgctagtt 960
 acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa

<210> 6

<211> 2313

20 <212> DNA

<213> Human

<400> 6

25 ccagagcagg cctgggtggtg agcaggggacg gtgcaccgga cggcgggagc gagcaaatgg 60
 gtctggccat ggagcacgga ggggtcctacg ctcgggcggg gggcagctct cggggctgct 120
 ggtattacct gcgctacttc ttctctctcg tctccctcat ccaattcctc atcatcctgg 180
 ggctcgtgct cttcatgggtc tatggcaagg tgcacgtgag cacagagtcc aacctgcagg 240
 30 ccaccgagcg ccgagccgag ggcctataca gtcagctcct agggctcacg gcctcccagt 300
 ccaacttgac caaggagctc aacttcacca cccgcgccaa ggatgccatc atgcagatgt 360
 ggctgaatgc tcgcccgcag ctggaccgca tcaatgccag ctccgcgcag tgccagggtg 420
 accgggtcat ctacacgaac aatcagaggt acatggctgc catcatcttg agtgagaagc 480
 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcatgctga 540
 atcagaaggt gaagacgctg gaggtggaga tagccaagga gaagaccatt tgcactaagg 600
 35 ataaggaaaag cgtgctgctg aacaaacgag tggcggagga acagctgggt gaatgcgtga 660
 aaacccggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaagggtga 720
 agccctctgc ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780
 ggactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atccccctggg 840
 40 ctcggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900
 ggtggaggag ctggcccggg gcctccgggc ggatatcgaa cgcgtggccc gcgagaactc 960
 agacctccaa cgccagaagc tggaagccca gcagggcctg cgggccaagt aggaggcgaa 1020
 acagaagggt gagaaggagg ctacggcccg ggaggccaag ctccaagctg aatgctcccg 1080
 gcagacccag ctacgctgga aggagaaggc ggtgctgcgg aaggaacgag acaacctggc 1140
 caaggagctg gaagagaaga agaggaggc ggagcagctc aggatggagc tggccatcag 1200
 45 aaactcagcc ctggacacct gcatcaagac caagtgcag ccatgaccca gctagcctgg aggagttcaa 1320
 gccccatggg cctgtcccca acccccagcc catcgaccca gctagcctgg catccagtgg 1380
 gaggaagatc ctggagtccc agaggccccc tgcaggcatc cctgtagccc catccagtgg 1440
 ctgaggaggc tccaggcctg aggaccaagg gatggcccga ctcgggcggt tgcggaggat 1500
 50 gcagggatat gctcacagcg cccgacacaa cccctctccc cgcgagatg acgtcacgca agcaacggcg 1620
 ccaccatcag acaactccct gcatgcaaac ccttagtacc ctctcacacc caccacggcg 1680
 cctcacgac cctcaccag agcacacggc gcggagatg acgttagacgt cacgaagaga 1740
 ctgacgtcac atataccgt ggtgatggcg tcacgtggcc atgttagacgt acttggcatg 1800
 tatagcgatg gcgtcgtgca gatgcagcac gtcgcacaca gacatgggga acttggcatg 1860
 55 acgtcacacc gagatgcagc aacgacgtca cgggcatgt cgacgtcaca catattaatg 1920
 tcacacagac gcggcgatgg catcacacag acggtgatga tgatggcac agacacagtg 1980
 acaacacaca ccatgacaac gacacctata gatattggc cactcctccc cgacctggc 2040
 ccctttcaca cacactttct acccaattct cccctcccgc acagccctgg gccccagcac 2100
 acacggggcca aggtacccac aggtacccat ccaacttctc acccccagtg cctggacccc 2160
 60 ctccccctct ccagcttctt ggctcccag cctcttgagc gtgagtgtt ccaggacccc 2220
 gaggtgagaa caggaagcca ttcacctccg ctctgtgagc ggaggggagc cactccttct 2280
 ctcgggggccc tgagccgggg gtgaggggtc cctgtgtgct ttgaaatgtt ggtggcactt aataaatatt
 cccccaactc ccagccctgc ctgtggcccg ttgaaatgtt ggtggcactt aataaatatt
 agtaaatcct taaaaaaaaa aaaaaaaaaa aaa

65 <210> 7

<211> 389

<212> DNA
<213> Human

<400> 7

5 gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
10 tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgat atattggtct gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc

<210> 8

15 <211> 157
<212> DNA
<213> Human

<400> 8

20 tgcttttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

25 <210> 9

<211> 561
<212> DNA
<213> Human

30 <400> 9

aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttggtg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120
35 tgaactgaac tattctgtta catatggttg acaaactctgt gtgttatttc ttttctacct 180
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcca tgatgaacat 240
tccgtatttt ttgacctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
ttaaacctat aatgagtatt cttaatggag aattcctaat ggatggatta tcccctgatc 480
40 ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgccccaat ttctagga a

<210> 10

45 <211> 1508
<212> DNA
<213> Human

<400> 10

50 cacaaacacg agagactcca cggctctgcct gagcaccgcc agcctcctag gctccagcac 60
tcgcaggctc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtagcag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctctccggt gacctgttgc gatggcataa tccgggtgca acccaaatct 240
gagctcaagc caggtgagct taagccactg agcaaggaa atttgggcct gcacgcctac 300
55 aggtgtgagg actgtggcaa gtgcaaagt aaggagtgc cctacccaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
tgtgtctgac acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540
gggtctatgt cccctttttt gccttggtta ttggtgtacc ttccagccaa gggttgcctt 600
60 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaagt tcccactgtc ccccctagga actttgaaaa accaacaatg 720
catcattaat caggaatatt acagtaatga ggattttttt tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagtgg gatagtcttt 840
gctgttttgc gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
65 ctcagctaag ggagctcaa gtatgagata cagaacttgg tgacctatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaa tttttgtttg tgaatagtac ttgcaaaaact 1020

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatTTTT 1080
 gtatatacaa taatatTTTgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140
 cacaaaaatat tatactaata tgttggtacat tcggaagaat gtgaatcaat cagtattgtt 1200
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260
 ttcattgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320
 attgttttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaattttta 1380
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaa

<210> 11
 <211> 389
 <212> DNA
 <213> Human

<400> 11

20 gggcaggtga tcagggcaca catttcccgt ccattgagac agtagcattc ccggcaccca 60
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cgggtgagaca agtgcccagc 120
 aggatgggtg gccagctga agcacaggcc gctctgcact tgcagataag acagccgtga 180
 ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgctca 300
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360
 acctcggccg cgaccacgct ggggtaccga

<210> 12
 <211> 981
 <212> DNA
 <213> Human

<400> 12

35 tttttttttt ttggattgca aaaattttatt aaaattggag acactgtttt aatcttcttg 60
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120
 cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggtcattaaa aaccctagtt 240
 taggataaca acatattaat cagggcaaaa taaaaatgtg tgatgcttgt tagtagagta 300
 acctcagaat caaaatggaa cggttttaca gtgatatcat tatatttcat ttggcagaat 360
 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420
 40 taggataaca ggtctgcctg tttgaagatg aaaaataata cccattttaa atttgcctta 480
 ctcaatttcc ttctcagtca cattttaact tttaaacagc taatcactcc catctacaga 540
 ttaagggtga tatgccacca aaaccttttg ccaccttaaa aatttccttc aaagttaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
 cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720
 45 taccaggagc agaaccatta agctgggtcca ggcaagttgg actccaccat ttcaacttcc 780
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
 agtagctatt ctcatccttc cttggggaca caactgtcca taaggtgcta tccagagcca 900
 cactgcatct gcacccagca ccatacctca caggagtcca ctcccacgag ccgcctgtat 960
 ataagagttc ttttgatgac g

<210> 13
 <211> 401
 <212> DNA
 <213> Human

<400> 13

60 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120
 tctctcccc agagcgaccc cccgggcagg ctggggccca aggaatgacc cagcaactgc 180
 tccctaccca gcacactctc ttactgcca cctgcaatta tgctgtgaag atgactgggt 240
 gtggatcatca cgattcagag aaatcaagat ctatgacat tttaggcaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360
 acttcagcat atttagttgt cattaaaatt aagctgatat t

<210> 14

<211> 1002
 <212> DNA
 <213> Human

5 <400> 14

10 gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
 acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
 tttgaaaatg ttaaatacaa gtcctattct ctttgtccag ctgggttag ctagaggtag 180
 ccaattactt ctcttaaggt ccattggcatt cgccaggatt ctataaaagc caagttaact 240
 gaagtaaaata tctggggccc atcgcacccc cactaagtac tttgtcacca tgttgatct 300
 taaaagtcatt ttttactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
 ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gactgatttt 420
 tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
 15 tactgaaaac aatgggtgcca tatgtccaa agacatttcc ccaagataac tgccaaagag 540
 tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
 attaatacag ctcaaatgga gtagtaacca agcttttctg cccagggaagt aacaaacatc 660
 actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacattc 720
 attcaataaaa cattagccaa gctaattgtc caagccactg tgccagggtat taacaatata 780
 20 acaacaataa aagacacagt ccttcctctc aaggtgttca gtctagtagg gaagatgatt 840
 attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaatctct 900
 gcctatgttc tcagatatcc tgggttaggtc agggatggga acccaaaatc aattctttta 960
 acaaacacta aaggtgattc taacacaggc ggtgtgagga cc

25 <210> 15
 <211> 280
 <212> DNA
 <213> Human

30 <400> 15

35 cgaggtgggc caccgtgtc tggcttgaga tttttaaatg aggattacat tatcctattt 60
 ataattattcc tattctaatc tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
 aaacattatt agaaacaaa tgccataatc cttataagac taaaaaaatc accaagatga 180
 aactgtatta tgactctcaa tttttaaaca ttttaaaaaa tgttagtggt ttgtaagcac 240
 caatcttaac tatttcacct gcccgggcgg ccgctcgagg

40 <210> 16
 <211> 2041
 <212> DNA
 <213> Human

<400> 16

45 cccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60
 atagagggtta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
 cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
 atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
 aattttgtta ttgccttctt tagagacttt ataattctta gttgattttc aaggacttga 300
 50 atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
 ttacctctag catcaattct tttataaaga atgttaaata aattacattt tttgttcagt 420
 aaaactgaag atagaccatt taaatgtctt taccaaattt aacgcagctt aattagggac 480
 caggtagata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
 gaatttttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
 55 ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaaga 660
 tagatatttg ttatagtctg acatttttaac agtcatagta tttagcgttt cgtgaccagt 720
 gcatttttga ctctctcagg atcaaaaatac gagtctgcca actgtattaa atcctcctcc 780
 accccctcca ccagttgggc cacagcttcc tgggtgggtc ttgtcatcaa atccattggg 840
 ccgaaatgaa catgaagcag atgcagcttg gagggcccgg gctcgagcat tcaactcttg 900
 60 ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
 tgggtctcca tttatccaga gtccactggt tgggttatta ccacttaaac cattagtagt 1020
 atgctgtttt ttatacaaaa gcacataaag tctgtccttt ggaaacctgc tcgtaatttt 1080
 ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaaataaaa acccattctt 1140
 ttgacatttc cttattttcc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200
 65 gtaaatgact ctgggaggat gctaattgcca gagcctcaga ctgggtgtac atctgatatg 1260
 aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320

5 taccagagtg aaccacaacg gaacttaata gatagggcac caatthttgtg caggaagctt 1380
 catcagttccc tgaaggcttt aatthtttag caaggttctc actaagatca gtgaagtcaa 1440
 catctacaga ccaactttct gacaatgaag agaaagaagt aattcttcta actggcaact 1500
 ccaaaaccag tggccagtga tacattgtct aaaatthttcc ttctcacatg atacttctga 1560
 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgcata 1620
 gthtttctcag catthttgcag agaggcacag thttcacaaat aatattggtt atcaccagta 1680
 agaattctctg gagcccaaaa aataatthtag taagtcagtt actgaagggtg tggthttcacc 1740
 tcccggthttc tgagggtacat cthttattaac aagaattctg ttagattcgt tagggacaga 1800
 agtgthtttca gaacagtaaa actcattagg aggactgcct atggthttttt cattcacaaag 1860
 10 tgagtcacag atgaaggcag ctgthgttggt attataaact actggctctt ctgaaggacc 1920
 gggtagacag gcttgcatga gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980
 gacagacatg thttccaaag aagaggaagc acaaaacgca agcgaaagat ctgtaaaaggc 2040
 t

15 <210> 17
 <211> 235
 <212> DNA
 <213> Human

20 <400> 17

25 cgccccgggc aggtgtcagg ggtthccaaac cagcctgggg aaacacagcg tagacccttc 60
 acctctacaa ataaaaaatt aaaaaattag ccagggtgtg cagcgaaaca ctgtagtctc 120
 agatactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aaggthtacag 180
 tgggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta

<210> 18
 <211> 2732
 <212> DNA
 <213> Human

30 <400> 18

35 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60
 tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120
 aaatattatc ttcttggtga tcacattgtg caaatgggtg aagcattcaa acactttgaa 180
 accagattct agcaggttg aaacattaa gtcttgggtg cttggcgctt tcgctcttct 240
 gtgtcttctt ggcctcacct ggtccttttg gtgtctthtt attaatgagg agactattgt 300
 gatggcatat ctcttcacta tathaatgc thttccaggga gtgttcattt tcatctttca 360
 40 ctgtgctctc caaaagaaaag tacgaaaaga atatggcaag tgcttcagac actcatactg 420
 ctgtggaggc ctcccaactg agagtcacca cagttcagtg aaggcatcaa ccaccagaac 480
 cagtgctcgc tathcctctg gcacacagag tctgataaga agaattgtga atgatactgt 540
 gagaaaaaca tcagaattctt cthttatctc aggtgacatc aatagcactt caacacttaa 600
 tcaaggtggc ataaatctta atathattatt acaggactga catcacatgg tctgagagcc 660
 45 catcttcaag atthtatca thtagaggac atthactgaa caatgccagg gatacaagtg 720
 ccatggatac tctaccgcta aatggtaatt thaaacaacag ctactcgctg caaagggtg 780
 actataatga cagcgtgcaa gthgtggact gtggactaag tctgaatgat actgtthttg 840
 agaaaatgat catthtcagaa thagtgcaca acaacttacg gggcagcagc aagactcaca 900
 acctcgagct cagctacca gthcaaactg tgattggagg tagcagcagt gaagatgatg 960
 50 ctattgtggc agatgcttca thtttaatgc acagcgacaa cccagggtg gagctccatc 1020
 acaaagaact cgaggcacca cthattctc agcggactca ctcccttctg taccacccc 1080
 agaagaaagt gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140
 aagatcacct acagtcccc aacagagact ctctthtatac aagcatgccc aatcttagag 1200
 actctcccta tccggagagc agccttgaca tggaaaga cctctctccc tccaggagga 1260
 55 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320
 agatgtgcta ccagatcagc aggggcaata gtgatggta tataatcccc atthacaaag 1380
 aagggtgtat tccagaagga gatgttagag aaggacaaat gcagctggtt acaagtctt 1440
 aatcatacag ctaaggaatt ccaagggcca catgcgagta thaatataa aagacaccat 1500
 tggcctgacg cagctccctc aaactctgt tgaagagatg actcttgacc tgtggttctc 1560
 60 tgggtgtaaaa aagatgactg aactthgcag thctgtgaat thttataaaa catacaaaaa 1620
 cthttgtatat acacagatga tactaaagt aattatttgt tacaagaaa agagatgcca 1680
 gccaggtatt thaaagattct gctgctgttt agagaaattg tgaaacaagc aaaacaaaac 1740
 thttccagcca thttactgca gcagtctgtg aactaaattt gtaaatatgg ctgcaccatt 1800
 thttgtaggcc tgcattgtat tatatacaag acgtaggctt taaaatctg tgggacaaat 1860
 65 thactgtacc thactattcc tgacaagact tggaaaagca ggagagatat tctgcatcag 1920
 thttgcagttc actgcaaact thttacatta aggcaaagat tgaaaacatg cthtaaccat 1980

5 agcaatcaag ccacaggcct tatttcatat gtttcctcaa ctgtacaatg aactattctc 2040
 atgaaaaatg gctaaagaaa ttatatattt ttctattgct agggtaaaat aaatacattt 2100
 gtgtccaact gaaatataat tgtcattaaa ataattttta agagtgaaga aaatattgtg 2160
 aaaagctctt gggtgcacat gttatgaaat gttttttctt acactttgtc atggtaagtt 2220
 ctactcattt tcaattcttt tccactgtat acagtgttct gctttgacaa agttagtctt 2280
 tattacttac atttaaattt ctatttgcca aaagaacgtg ttttatgggg agaaacaaac 2340
 tctttgaagc cagttatgtc atgccttgca caaaagtgat gaaatctaga aaagattgtg 2400
 tgtcaccctt gtttattctt gaacagaggg caaagagggc actgggcact tctcaciaac 2460
 tttctagtga acaaaagggt cctattcttt tttaaaaaaa taaaataaaa cataaatatt 2520
 10 aetcttccat attccttctg cctatatatta gtaatttaatt tattttatga taaagttcta 2580
 atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640
 ttaataatga gcccatcact aatatccagt gtaaagttta acacggtttg acagtaaata 2700
 aatgtgaatt ttttcaagtt aaaaaaaaaa aa

15 <210> 19
 <211> 276
 <212> DNA
 <213> Human

20 <400> 19

25 ctccctaaat gatttttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60
 aaccgccttt gcatatTTTT tatgtacaaa tctttgtata caattccgat gttccttata 120
 tattccctat atagcaaacc aaaaccagga ccttccaact gcatgcctca agtccctgtg 180
 gagcactctg gcaactggat ggcctcactt gctttctgac aaaatagctg gaaaggagga 240
 gggaccaatt aaatacctcg gccgcgacca cgctgg

30 <210> 20
 <211> 2361
 <212> DNA
 <213> Human

<400> 20

35 attgtaccag ccttgatgaa cgtgggccct gcttcgcttt tgagggccat aagctcattg 60
 cccactgggt tagaggctac cttatcattg tctcccgtga ccggaaggtt tctcccaagt 120
 cagagtttac cagcagggat tcacagagct ccgacaagca gattctaaac atctatgacc 180
 tgtgcaacaa gttcatagcc tatagcaccg tctttgagga tgtagtggat gtgcttgctg 240
 40 agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcactg caggagaagg 300
 acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaacc 360
 ttgccaagag ccagcatctg gacagtgatg ggctggccca gattttcatg cagtatggag 420
 accatctcta cagcaagggc aaccacgatg gggctgtcca gcaatatac cgaaccattg 480
 gaaagtgtga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540
 tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccaccc 600
 45 tgctcctcaa ctgctatacc aagctcaagg acagctcgaa gctggaggag ttcataaaga 660
 aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaagggtc ctccggcagg 720
 ctggctacta ctcccatgcc ctgtatctgg cggagaacca tgcacatcat gagtgggtacc 780
 tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcggcaagc 840
 tgccctttga gcaggcagag agcaacatga agcgctacgg caagatcctc atgcaccaca 900
 50 taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg cccagcctcg 960
 aaggccgcag cgataggagg gccccaggct gcagggccaa ctctgaggag ttcateccca 1020
 tctttgccaa taaccgcgca gagctgaaaag ccttcctaga gcacatgagt gaagtgcagc 1080
 cagactcacc ccaggggatc tacgacacac tctttgagct gcgactgcag aactggggcc 1140
 acgagaagga tccacaggtc aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200
 55 gtggtcgctt ctgcgacgtc tttgacaagg cctgtgtcct gtgccagatg cagcacttcc 1260
 aggatgggtg cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcaactacc 1320
 acatgcagca cgagcagtac cggcaggtca tcagcgtgtg tgagcgccat ggggagcagg 1380
 acccctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440
 agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgcca cctcttctag 1500
 60 tgggtgcagac cctggccac aactccacag ccacactctc cgtcatcagg gactacctgg 1560
 tccaaaaact acagaaacag agcccagaga ttgcacagga tgagctgcgg gtgcggcggt 1620
 accgagagga gaccacccgt atccgcccagg agatccaaga gctcaaggcc agtcctaaga 1680
 ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagttgccc tcagtccact 1740
 65 tcctgtgtgg ccaactcctc caccaacact gctttgagag ttactcgga agtgatgctg 1800
 actgccccac ctgcctccct gaaaaccgga aggtcatgga tatgatccgg gcccggaac 1860
 agaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920

ctgtgattgc tgactacttt ggcagaggtg ttttcaacaa attgactctg ctgaccgacc 1980
 ctcccacagc cagactgacc tccagcctgg aggctgggct gcaacgcgac ctactcatgc 2040
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100
 5 agaacagaca caatgggacc tgggcgggcg ttacacagaa ggctggctga catgcccagg 2160
 gctccactct catctaattgt cacagccctc acaagactaa agcggaactt tttcttttcc 2220
 ctggccttcc ttaattttta gtcaagcttg gcaatccctt cctcttttaac taggcaggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaacc tcctgaagtt 2340
 ttggaaaaaa aagctgggtt c

10 <210> 21
 <211> 179
 <212> DNA
 <213> Human

15 <400> 21

aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60
 acaatcaact aaaggaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120
 tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

20 <210> 22
 <211> 905
 <212> DNA
 <213> Human

25 <400> 22

30 tttttttttt ttcttttaacc gtgtggtctt tatttcagtg ccagtgttac agatacaaca 60
 caaatgttcc agttagaagg aattcaaacg gaatgccaaag gtccaagcca ggctcaagaa 120
 ataaaaaggg aggtttggag taatagataa gatgactcca atactcactc ttccaaagg 180
 caaagggtact tttgatacag agtctgatct ttgaaactgg tgaactcctc ttccacccat 240
 taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtggtgggaa 300
 tagggtcatt aataactatg aatatactct ttagaagggtg accatttttg acttttaaagg 360
 gaatcaattt tgaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaa 420
 35 gggagcttga agagccttgg aagtttctat tacaataaga gcaccatata cttcatgcca 480
 aatctcaaca aaagctcttt ttaactccat ctgtccagtg tttacaaata aactcgcaag 540
 gtctgaccag ttcttggtta caaacataca tgtgtgtgtc tgtgtgtata cagcaatgca 600
 cagaaaaggc taccaggagc ctaatgcctc tttcaaact tgggggaacc agtagaaaaa 660
 ggcagggtc cctaattgtc attattacat ttccattccg aatgccagat gttaaaagt 720
 40 cctgaagatg gtaaccagc tagtgaggaa taaatacccc accttgccca gtccacagag 780
 aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaagtgag tgttttttcg 840
 ccattgattg cagtcccttc ctccagacca gctgcttatt tcctcagggg cccagggaat 900
 gttga

45 <210> 23
 <211> 2134
 <212> DNA
 <213> Human

50 <400> 23

55 ggtctcttct ttcttttttt tttttccaaa agtggtcttt tatttctagt aacatatatt 60
 gtataaatac tctattttat atgcacttcc acaaaagcga tataatttaa aagttttttt 120
 cattagaaat aaatgtataa aaataaatat gttattatag gcatttatta ctaactatag 180
 tccttcttgg aaggaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240
 tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300
 accaggatac gactgttgga ccagctgctg gagatggacc tgctacccct cagcagcctc 360
 cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggacctgt tctacacacc 420
 60 tcatttttgg tccggcgttt catcctcctt gtgtgattgt actgattttc atgagacaca 480
 agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaaggaagt 540
 tggagggtact aagctcattg tgtctcctct agcttttacc agcatctaatt gcttcaactgc 600
 tttttttcca ttgtagactt taatgcactt gaataaatac atggagttgt tttttcctca 660
 aaatgaatta cacaaataaa gactgagatg gtccaaaaaa ggaaagagga agccatttgc 720
 gttatttcac gttgctgagc ctttctctca tgttgaaaca tctgaagttt taattctcgg 780
 65 tagaaaatat gtataaacat tctctgaaac catagcagc ataaacagtg ctggtcaaaag 840
 atcctatttg tactcctttc tccccccatt gttagtgagg taaagtaaaa cagggtcttag 900

5 taaaatctca cttttctcct acttttcatt tcccaacccc catgatacta agtattttgat 960
 aagtaccagg aaacaggggt tgtaatatgt ctaacttttt ttgacaattg ctttgttttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccgg ggctttatta 1080
 tgctatatca ctgctcagag gtttaataatc ctcactaact atcctatcaa atttgcaact 1140
 ggcagttttac tctgatgatt caactccttt tctatctacc ccataaatcc caccttactg 1200
 atacacctca ctgggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260
 gcaccagccc ttctcactt tgctttgccc tcaaagctaa caccacttaa accacttaac 1320
 tgcaattctgc cattgtgcaa aagtctatga aatgttttagg tttcttttaa ggatcacagc 1380
 10 tctcatgaga taacaccctt ccatcatggg acagacactt caagcttctt tttttgtaac 1440
 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 ggtctgcaca aggtctgggt ctggctgggt tctacttctt tgcacactcg gaagcaggct 1560
 gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680
 ccttcttctt ctttacgaag taggtgtatt taatttttagg tcgaagggca ttgccacag 1740
 15 taagaacctg gatggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800
 ccgcagagga gccgctgtac ctcaagacaa caccttttga cataatgtct tgctctaagg 1860
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
 agtgcaccat gttcctggat cccctctggg tccgctggtt cacttcgatg ttggtggctc 1980
 cagttggaat tgtgatgata tcatgatatc cagggttttg actagtaact gatcctgata 2040
 20 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttcttttttg 2100
 agtctatgat gcgatcacia ccagctttta caca

<210> 24

<211> 1626

25 <212> DNA

<213> Human

<400> 24

30 ggacaatttc tagaatctat agtagtatca ggatatattt tgcttttaaaa tatatttttg 60
 ttattttgaa tacagacatt ggctccaaat tttcatcttt gcacaatagt atgacttttc 120
 actagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gtttaaggctg 180
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacagggt gaacaaacgt 240
 35 agttgttttt tactgatact aaatgttggc tacctgtgat tttatagtat gcacatgtca 300
 gaaaaaggca agacaaatgg cctcttgtag tgaatacttc ggcaaaactta ttgggtcttc 360
 attttctgac agacaggatt tgactcaata tttgtagagc ttgcgtagaa tggattacat 420
 ggtagtgtat cactggtaga aatggttttt agttattgac tcagaattca tctcaggatg 480
 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggtttttag 540
 40 aaagctttgt ctaaaaattt ggcctaggaa tggttaacttc attttcagtt gccaaaggggt 600
 agaaaaataa tatgtgtgtt gttatgttta tggttaacata ttattaggta ctatctatga 660
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
 ccatttagcc cagtgggaaa gtcttggaac tcaggttacc cttgaaggat atgctggcag 780
 ccattctctt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttga 840
 45 tctggaatgc attagttatg ccttgtagca tttccagaat ttcaggggca tcgtgggttt 900
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
 50 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200
 cgttgtttct taggggtcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtag tgcaatcaca 1320
 atgccagatg gtgtttatgg gctattttgt taagtaagtg gtaagatgct atgaagtaag 1380
 tgtgtttgtt ttcattctat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440
 55 tgggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatattg 1500
 attataacctg tcacgcttct agttgcttca accatttttt aaccattttt gtacatatatt 1560
 tacttgaaaa tatttttaaa ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620
 aaaaaa

<210> 25

60 <211> 1420

<212> DNA

<213> Human

<400> 25

65

gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60

5 ttcattgaaa tccttgctac ttctcttccct cctcaatgaa agacacgaga gacaagagcg 120
 acacaagctt aagaaaaacg agcaaggaag agtatcttca ttattctcat tttctctgag 180
 ttggaaacaa aaacatgaag gactccaact agaagacaga tattttacatt taaatagatt 240
 agtgggaaaa ctttaagagt ttccacatat tagttttcat tttttgagtc aagagactgc 300
 10 tccttgtagt gggagacact agtagtatat gtttgtaatg ttacttttaa attatctttt 360
 tattttataa ggcccataaa tactgggttaa actctgttaa aagtgggcct tctatcttgg 420
 atggtttcac tgccatcagc catgctgata tattagaaat ggcatcccta tctacttact 480
 ttaatgctta aaattatata taaaatgctt tatttagaaa acctacatga tacagtgggtg 540
 tcagccttgc catgtatcag tttcacttga aatttgagac caattaaatt tcaactgttt 600
 aggggtggaga aagaggtagt ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660
 atccttttgc tgggaggaga gttactcttg aaaggcaggc agcttaagtg gacaatgttt 720
 tgtatagtag tgagaatttt acgacacttt taaaaattgt aatgtccagt 780
 15 tttgctctgt tttgcctgaa gtttttagtat ttgttttcta ggtggacctc tgaaaaccaa 840
 accagtacct ggggagggtta gatgtgtgtt tcaggcttgg agtgtatgag tggttttgct 900
 tgtattttcc tccagagatt ttgaacttta ataattgctg gtgtgttttt ttttttttaa 960
 gtggctttgt ttttttttct caagtaaaat tgtgaacata tttcctttat aggggcaggg 1020
 catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080
 tcgacacatt ttttttcagt aacttgaaaa ttcaaaaggg acatttggtt aggttactgt 1140
 20 acatcaatct atgcataaat ggcagcttgt tttcttgagc cactgtctaa attttgtttt 1200
 tatagaaatt ttttatactg attggttcat agatggtcag ttttgtacac agactgaaca 1260
 atacagcact ttgccaaaaa tgagtgtagc attgttttaa cattgtgtgt taacacctgt 1320
 tctttgtaat tgggttgtgg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380
 agtaataaaa gtgtccttta acttcaaaaa aaaaaaaaaa

25 <210> 26
 <211> 689
 <212> DNA
 <213> Human

30 <400> 26

35 aaacaaacaa aaaaaaagtt agtactgtat atgtaaatac tagcttttca atgtgctata 60
 caaacaatta tagcacatcc ttctttttac tctgtctcac ctcttttagg tgagtacttc 120
 cttaaataag tgctaaacat acatatacgg aacttgaaag ctttggttag cttgacctta 180
 ggtaatcagc ctagttttaca ctgtttccag ggagtagttg aattactata aaccattagc 240
 cacttgcttc tgcaccattt atcacaccag gacagggctc ctcaacctgg gcgctactgt 300
 catttggggc caggtgattc ttctttgcaa gggctgtcct gtacctgccc gggcgccgcg 360
 tcgaagcgtg gtcgcggccg aggtactgaa aggaccaagg agctctggct gccctcagga 420
 40 attccaaatg accgaaggaa caaagcttca gggctctggg tgggtgtctc cactattcag 480
 gaggtggctg gaggtaacgc agcttcattt cgtccagtc tttccagtat ttaaagttgt 540
 tgtcaagatg ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600
 ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660
 cacaccaga gcctgaagtt tgtccttcg

45 <210> 27
 <211> 471
 <212> DNA
 <213> Human

50 <400> 27

55 tcccagcggc atgaagtttg agattggcca ggccctgtac ctgggcttca tctccttcgt 60
 ccctctcgtc cattggtggc accctgcttt gctgtcctg ccaggacgag gcacctaca 120
 agccctaacc caggcccccgc ccaggccac cagcaccact gcaaacaccg cactgccta 180
 ccagccacca gctgcctaca aagacaatcg ggccccctca gtgacctcgg ccaccacagc 240
 gggtagcagg tgaacgacta cgtgtgagtc cccacagcct gcttctcccc tgggctgctg 300
 tgggctgggt cccggcgagg ctgtcaatgg aggcaggggt tccagcacia agtttacttc 360
 tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420
 60 ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a

<210> 28
 <211> 929
 <212> DNA
 <213> Human

65 <400> 28

5 ggtgaactca gtgcattggg ccaatgggtc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acggtttggc tgctgggtgg ctttccctc actgtcattg gaggcattct 120
 tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgcccggga 180
 gattccaccc cagccctggt acaagtctac tgtcatccac atgactgttg gaggcttcct 240
 gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtacact ttgtacggca tctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360
 ttgcatctcc attgcaactca cctacttcca gttgtctggg gaggattacc gctgggtggtg 420
 10 gcgatctgtg ctgagtgttg gctccaccgg cctcttcac ttctctact cagttttcta 480
 ttatgcccgg cgctccaaca tgtctggggc agtacagaca gtagagttct tcggctactc 540
 cttactcact ggttatgtct tcttctcat gctgggcacc atctcctttt tttcttccct 600
 aaagttcatc cggatatatc atgttaacct caagatggac tgagttctgt atggcagaac 660
 tattgtgttt cttccctttt cttcatgccc ttgtgaactc tcctaccagc ttctcttctg 720
 15 attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattccttcc 780
 ccagagaggg cctggaaatt ataaatctct atcacataag gattatatat ttgaactttt 840
 taagttgcct ttagtttttg tctgtatttt tctttttaca attacaaaaa taaaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa

20 <210> 29
 <211> 1775
 <212> DNA
 <213> Human

25 <400> 29

30 gaacgtgatg ggaacttttg gaggatgtct gagaaaatgt ccgaagggat tttggccaac 60
 accagaaaac gccaatgtcc taggaattcc ctcccaaat gcttcccaa aaattactca 120
 ttgacaattc aaattgcact tggctggcgg cagcccgggc ggccttcagt ccgtgtgggg 180
 cgcccgctg gccttctcct cgtaggactc cccaaactcg ttcactctgc gtttatccac 240
 aggataaagc caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300
 cagccggtga gacgtgggca tggtgatgat gaaggcaaa acgtcatcaa tgaagggtgt 360
 gaaagccttg taggtgaagg ccttcagggg cagatgtgcc actgacttca acttgtagtt 420
 cacaaagagc tggggcagca tgaagaggaa accaaaggca tagacccgtg tgacgaagct 480
 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
 35 cccgacacag agaggggtaca gcaggtatga caagtacttc atggcctgag tatcgtactc 600
 ctcggttttc ctctcagatt cgctgtaagt gccaaactga aattcgggca tcaggcctct 660
 ccaaaaaata gtcattctca atgccttctt cactttccac agctcaatgg cggctccaac 720
 acccgccggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780
 cacggtgctg aagcagcgcc agagcactgc cttggtggac atgccgatca tgctcttctt 840
 40 cttcttccag aaactgatgt cattttttaa ggccaggaaa tcaaagagaa gatggaacgc 900
 tgcgacaaa aggttcagcg ccaggaagta taagttggta tctacaaaaa ttcctttcac 960
 ctcatcagca tctttctctg aaaacccgaa ctgctgcagg gagtacacgg cgtcctgcat 1020
 gtggatccag aagcgagcc gccccagtga gacctgtcgc taggacacgg tgaggggcag 1080
 ctcggtggtg gagcggttta tgaccatcag gtccttcacg cggttgctga gctggtcgat 1140
 45 gaacaggatg ggcaggtaat gcacggtttt cccagctgg atcatcttca tgtaccgatg 1200
 cacatcgcca ggcagggagg acccgtaaaa gacaaagtgt tccgccatca cgttcagcgc 1260
 cagcccggtg cgccagtggg aactggctc atccagggca ctgctcggct tcttctccgc 1320
 ctcgatctgc tgtgtatcag actccccggt gagcagggtg atttcttctg gcttggggag 1380
 catgtagggt gtcagaggac tgaccaggt cacttgcttc ccgtcgtgcc acggcaggac 1440
 50 cccagcgtga tggaggaaga ttaggcata cagcgtccca ttgtttctcg ttttcttttg 1500
 tacagaaaca ttaactgtcc tttaaattt ggactccaca tcaaagtctt ccacattcaa 1560
 gaccaggtcg atgttgttct cagcaccag gtgggacctc gtcgtggtgt acacgctcag 1620
 ctgcagcttg ggccgcccgc ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680
 55 gcgggtgtag acgatgccgt acatgacca gcagggtgtg accacgtaga ccacgaacac 1740
 gccaccacc aagctggtga aggagctgcg gcccc

60 <210> 30
 <211> 1546
 <212> DNA
 <213> Human

65 <400> 30

aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgctaatt 60
 aaggccctgc caggctggga ggaattgtc cctgcctgct tctggagaaa gaagatattg 120

5 acaccatcta cgggcacccat ggaactgctt caagtgacca ttctttttct tctgcccagt 180
 atttgcagca gtaacagcac aggtgtttta gaggcagcta ataattcact tgttggtact 240
 acaacaaaac catctataac aacaccaaac acagaatcat tacagaaaaa tgttggtcaca 300
 ccaacaactg gaacaactcc taaaggaaca atcaccaatg aattacttaa aatgtctctg 360
 atgtcaacag ctactttttt aacaagtaaa gatgaaggat tgaaagccac aaccactgat 420
 gtcaggaaga atgactccat cattttcaaac gtaacagtaa caagtgttac acttccaaat 480
 gctgtttcaa cattacaaag ttccaaaccc aagactgaaa ctcagagttc aattaaaaca 540
 acagaaatac caggtagtgt tctacaacca gatgcatcac cttctaaaac tggtagatta 600
 10 acctcaatac cagttacaat tccagaaaaac acctcacagt ctcaagtaat aggactgag 660
 ggtgaaaaaa atgcaagcac ttcagcaacc agccggtctt attccagtat tattttgccg 720
 gtggttattg ctttgattgt aataacactt tcagtatttg ttctggtggg tttgtaccga 780
 atgtgctgga aggcagatcc gggcacacca gaaaatggaa atgatcaacc tcagtctgat 840
 aaagagagcg tgaagcttct taccgttaag acaattttct atgagtctgg tgagactct 900
 15 gcacaaggaa aaaccaagaa ctgacagctt gaggaattct ctccacacct aggcaataat 960
 tacgcttaat cttcagcttc tatgcaccaa gcgtggaaaa ggagaaagtc ctgcagaatc 1020
 aatcccgcag tccatacctg ctgctggact gtaccagacg tctgtcccag taaagtgatg 1080
 tccagctgac atgcaataat ttgatggaat caaaaagaac cccggggctc tcctgttctc 1140
 tcacatttaa aaattccatt actccattta caggagcggt cctaggaaaa ggaatttttag 1200
 20 gaggagaatt tgtgagcagt gaatctgaca gccaggaggg tgggctcgct gataggcatg 1260
 actttcctta atgtttaaag ttttccgggc caagaatttt tatccatgaa gactttccta 1320
 cttttctcgg tgttcttata ttacctactg ttagtattta ttgtttacca ctatgttaat 1380
 gcagggaaaa gttgcacgtg tattattaaa tattaggtag aaatcatacc atgctacttt 1440
 gtacataata gtattttatt cctgctttcg tgttactttt aataaataac tactgtactc 1500
 25 aatactctaa aaatactata acatgactgt gaaaatggca aaaaaa

<210> 31
 <211> 750
 <212> DNA
 <213> Human

30
 <400> 31

35 cacttgggca cccccatttt ctaaaaaaat ggaaatctgg agggcaaaaa aggtgtgctg 60
 aagggaagtg cctctgatgg cccaaaaacc ttcttccaaa ctagtgtagg aatggaatgg 120
 atagcaaatg gatccctttt ggctcctttt ggagcatgcc ttccctatct tatccttggc 180
 ccactaaag cagaacgtta cggatatctt tgtttttgcc attggatgcc tacttgcca 240
 aacagccttt ccctaattgg aaaatgcagt cctgttttaa acctttgatt tacgactact 300
 40 tgtacatgct tgctcattac aattttgaca ttttttacat agtgaagacc ccaacatat 360
 cagtgaaca tgacaagatc ataaagaaca gtatcatatt attatttagt cgcttttaca 420
 gtggcaagcc aattttgaaa tatctcattt aaaactcaga cccaattcac tgagttatac 480
 ttttaatagc ttctcagca cactatttcc catgcattaa atatgataaa ataactctac 540
 actgcccata ggtcttgtaa aaagggaagtc tgaatacaga gccacaaca ctaaaattgt 600
 ttttctagct acaaagtata gcatcatcaa cacagacacg atttggactc cctgacagg 660
 45 ggattggaaa acggtgttta aagagaagag aacattttta cataaatgtc attaagaatc 720
 ccaaaggcct tatttgtcac caccgtcccc

<210> 32
 <211> 1620
 <212> DNA
 <213> Human

<400> 32

55 gcaattcccc cctcccacta aacgactccc agtaattatg tttacaaccc attggatgca 60
 gtgcagccat tcataagaac cttggtgccc cagaaaaatc tgtccttttt ggtaccaaac 120
 ctgaggtctt ttggaagata atgtagaaaa ccactaccta ttgaaggcct gttttggcta 180
 atctgtgcaa actctgatga tacctgcctt atgtggattc ttttccacac tgctttcatt 240
 60 ttttaagtata aagacttaga aaactagaat aatgctttta caaataatta aaagtatgtg 300
 atgttctggg ttttttctt ctttttagaa ccccgctccc atttaaaaaa ttaaaaaaaa 360
 aaaaaaaact ttttaacattt aaaaaataaaa aattaacaaa atttcactta tccaggaca 420
 cgctggcatt tggactcaat gaaaagggca cctaaagaaa ataaggctga ctgaatgttt 480
 tccataattt tcacacaata acagtccctt tctatccagc ttgccttcca tttatctcta 540
 gggttagctt ttcaggcaac atccttggtc attgcccaga aagtacctga gctatcagtg 600
 65 attggaatgg cacaggaaac cgaatcacat gggtgccctc cccttggttt tcaagtatct 660
 tggagtgttg cacaaaaatt aggtcatgcc ttcagtgtct tgttctttta acctaccctt 720
 tgacaatcag gtgctaataa ttgtatacta ttaaaaccag cacataagta ttgtaaagt 780

	gtgttcctcc	taggttgga	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgattttgt	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
5	tcgcaaactc	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
	cagtattatg	tttacaatcc	attggatgag	tgcagcatta	taagaccttg	gtgcccagaa	1080
	aaatctgtcc	tttttggtag	caaacctgag	gtcttttggg	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaactct	tgcaaaactc	gatgatacct	gcttatgtgg	1200
	attcttttcc	acactgcttt	cattttttaag	tataaagact	tagaaaaacta	gaataatgct	1260
10	tttacaata	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaaccctgt	1320
	atttaaacaa	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatattg	tgttcctaata	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tccccttgag	tagacacatca	1500
	acatacagca	ttgtacatta	caatgaaaat	gtgtaactta	aggggtattat	atatataaat	1560
15	acatatatac	ctttgttaacc	tttatactgt	aaataaaaaa	gttgcttttag	tcaaaaaaaa	1620
	<210>	33					
	<211>	2968					
	<212>	DNA					
	<213>	Human					
20	<400>	33					
	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
25	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
	gaaagtgaag	gcagtgaagg	tgatgaggaa	gatgaaaagg	tgtcagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaaagtaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgata	ggactaaaga	agaaagggct	tatgacaaag	caaaacggag	gattgagaaa	300
	cggcgacttg	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
30	gtacttgggc	atgtggacac	aggggaagaca	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	tggtatcaca	caacaaattg	gggccaccaa	tgttctctct	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	gtacggatt	540
	ccagtaattgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccatttta	gttggttgata	ttatgcatgg	tttggagccc	660
35	cagacaattg	agtctatcaa	ccttctcaaa	tctaaaaaat	gtcccttcat	tgttgactct	720
	aataagattg	ataggttata	tgattggaaa	aagagtcctg	actctgatgt	ggctgctact	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	ctttggtagc	tacctctgca	catactgggtg	atggcatggg	aagtctgata	960
40	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgcaca	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgtc	1080
	atcttgatca	atgggctgtt	gaaggaagga	gatacaatca	ttgttctctg	agtagaaggg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctctct	ctatgaagga	attacgagtg	1200
45	aagaaccagt	atgaaaagca	taaagaagta	agggcagctc	agggggtaaa	gattcttggg	1260
	aaagacctgg	agaaaacatt	ggctgggtta	cccctccttg	tggcttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttctttgga	agctctactg	1440
	gaatttctga	aaacatcaga	agtgccttat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
50	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagtgt	aggagttaga	1620
	attttttagt	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaatttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taattctcga	gatccgatag	tgatgggggt	gacggtggaa	1800
	gcaggctcagg	tgaaacaggg	gacacccatg	tgtgtcccaa	gcaaaaattt	tgttgacatc	1860
55	ggaatagtaa	caagtattga	aataaaacct	aaacaagtgg	atgttgcaaa	aaaaggacaa	1920
	gaagtttgtg	taaaaaataga	acctatccct	gggtgagtcac	ccaaaatggt	tgaagacat	1980
	tttgaagcta	cagatatctc	tgtagtaag	atcagccggc	agtccattga	tgactcaaaa	2040
	gactggttca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
	gtatttgaaa	tcatctaatt	ttttcacatg	gagcaggaac	tggagtaaat	gcaatactgt	2160
60	gttgtaatat	cccaacaaaa	atcagacaaa	aaatggaaca	gacgtatttg	gacactgatg	2220
	gacttaagta	tggaggaag	aaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttaact	ggtttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgccctgtt	2340
	actcacctct	cccttcccca	acccttctct	acttggctgc	tgttttaaag	tttgcccttc	2400
	cccaaatgtg	gattttttatt	acagatctaa	agctcttttcg	attttatact	gattaaatca	2460
65	gtactgcagt	atgtgattaa	aaaaaaaaaa	gcagatttttg	tgattcttgg	gacttttttg	2520
	acgtaagaaa	tacttcttta	tttatgcata	ttcttcccac	agtgattttt	ccagcattct	2580
	tctgccatat	gccttttaggg	cttttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgctttgtg 2700
 agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760
 catccaccag taagcaagct ctgttaggct tccatgggta gtggtagctt ctctcccaca 2820
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880
 5 ggtatgccag cacctgggta acagtaggag attttataca ttaatctgat ctgtttaatc 2940
 tgatcgggtt agtagagatt ttatacat

<210> 34

<211> 6011

10 <212> DNA

<213> Human

<400> 34

15

acggggcgcc ggacgaccgg cacatcttat cctccacgcc ccaactcgac tcggagcggg 60
 accgccccgg actccccctc gggccggcca ctcgaggagt gaggagagag gccgcccggc 120
 20 cggcttgagc cgagcgcagc acccccgcg ccccgcgcca gaagtttggt tgaaccgggc 180
 tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggaggagg 240
 ggaactcccc cggcccaagg ctctgtgggct cggggtcgcg cgcccgacga aggggcgggg 300
 tccgcccgcg aggggaggcg cccccgggga cccgagaggg gggtaggagc cgcgggctgc 360
 25 tgggtgcggcg gcggcagcgt gtgccccgcg caggggaggc gccgccccgc tcccggcccc 420
 gctgcgagga ggaggcggcg gcggcgcagg aggatgtact tggtaggggg ggacaggggg 480
 ttggccggct gcgggcacct cctggtctcg ctgctggggc tgctgctgct gccggcgcgc 540
 tccggcaccg gggcgctggt ctgcctgccc tgtgacgagt ccaagtgcga ggagcccagg 600
 aaccgccccg ggagcatcgt gcaggcgctc tgccgctgct gctacacgtg cgccagccag 660
 30 gggaacgaga gctgcggcgg caccttcggg atttacggaa cctgcgaccg ggggctgcgt 720
 tgtgtcatcc gcccccgct caatggcgac tccctcaccg agtacgaagc gggcgtttgc 780
 gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840
 attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900
 aatccctttg agtttccaag tcaggatatg tgcccttcag ctttaaagag aattgaagaa 960
 35 gagaagccag attgctccaa ggcccgcgtg gaagtccagt tctctccacg ttgtcctgaa 1020
 gattctgttc tgatcgaggg ttatgtctct cctggggagt gctgtccctt acccagccgc 1080
 tgctgtgtga accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140
 ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaaacca 1200
 gttttcggcg tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260
 40 ccggacagct atgaaactca agtcagacta actgcagatg gttgtgttac tttgccaaca 1320
 agatgcgagt gtctctctgg cttatgtggt ttccccgtgt gtgaggtggg atccactccc 1380
 cgcatagtct ctctgtggcg tgggacacct ggaagtgtct gtgatgtctt tgaatgtgtt 1440
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500
 cgaatggaca actgtcgggt ctgtcgtatg caagggggcg ttgccatctg cttcaccgcc 1560
 45 cagtgtgggt agataaaact cgagaggtac tacgtgcccg aaggagagtg ctgcccagtg 1620
 tgtgaagatc cagtgtatcc ttttaataat cccgctgggt gctatgccaa tggcctgatc 1680
 cttgcccacg gagaccggtg gcgggaagac gactgcacat tctgccagtg ctgcaacggt 1740
 gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagtgtatcc acctgcatgt 1860
 50 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgat 1920
 cacaatggtt gtcggacctg tcagtgcata aacacccagg aactatgttc agaacgtaaa 1980
 caaggctgca ccttgaactg tcccttcggg ttccctactg atgccccaaa ctgtgagatc 2040
 tgtgagtgcc gcccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
 cttggattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160
 55 ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtcacgg ctgtcttata 2220
 tgcaagtgca gagaggcctc tgcttcagct gggccaccca tctgtcggg cacttgtctc 2280
 accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
 tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccgggtgc tgcctgtggc 2400
 aacccccacca ttcaccctgg acagtgtctc ccatcatgtg cagatgactt tgtggtgcag 2460
 aagccagagc tcagtactcc ctccatttgc cagccccctg gaggagaata ctttgtggaa 2520
 60 ggagaaaact ggaacattga ctctgtact cagtgcacct gccacagcgg acgggtgctg 2580
 tgtgagacag aggtgtgccc accgtgtctc tgccagaacc cctcacgcac ccaggattcc 2640
 tctgcccac agtgtacaga tcaacctttt cgcccttcc tgtcccgcaa taacagcgta 2700
 cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760
 gacgtttgta ccagctgcat ctgcattgat agcgtaatta gctgtttctc tgaagcctgc 2820
 65 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgttgtcc ctactgcata 2880
 aaagacacaa ttccaaagaa ggtgggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940

gagcgggtggg accttgacag ctgcacccac tgctactgcc tgcagggcca gaccctctgc 3000
 tgcaccgtca gctgcccccc tctgccctgt gttgagccca tcaacgtgga aggaagtgtc 3060
 tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120
 5 aaccatcgag gagaggttga cctggaggtt cccctgtggc ccacgcctag tgaaaatgat 3180
 atcgtccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240
 cacccaagtg aagattcttc actggactcc attgcctcag ttgtggttcc cataattata 3300
 tgctctctta ttataatagc attcctattc atcaatcaga agaaacagtg gataccactg 3360
 ctttgctggt atcgaacacc aactaagcct tcttccttaa ataatcagct agtatctgtg 3420
 10 gactgcaaga aaggaaccag agtccagggtg gacagttccc agagaatgct aagaattgca 3480
 gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540
 gacaatttct accaaacagt gtgaagaaag gcaactagga tgaggtttca aaagacggaa 3600
 gacgactaaa tctgctctaa aaagtaact agaattgtg cacttgctta gtggattgta 3660
 ttggattgtg acttgatgta cagcgctaag acctactgg gatgggctct gtctacagca 3720
 15 atgtgcagaa caagcattcc cacttttctc caagataact gaccaagtgt tttcttagaa 3780
 ccaaagtttt taaagttgct aagatatatt tgctgtgaag atagctgtag agatatattg 3840
 ggtggggaca gtgagtttgg atggggaaag ggggtgggagg gtggtgttgg gaagaaaaat 3900
 tggtcagctt ggctcgggga gaaacctggt aacataaaag cagttcagtg gccagagggt 3960
 tatttttttc ctattgctct gaagactgca ctggttgctg caaagctcag gcctgaatga 4020
 20 gcaggaaaca aaaaaggcct tgcgacccag ctgccataac caccttagaa ctaccagcg 4080
 agcacatcag aaccttttga cagccatccc aggtctaaag ccacaagttt cttttctata 4140
 cagtcacaac tgcagtaggc agtgaggaag ccagagaaat gcgatatcggt catttctcta 4200
 aagcgggtta ttaaggatat atacagttac actttttgct gcttttattt tcttccaagc 4260
 caatcaatca gccagtttct agcagagtca gcacatgaac aagatctaag tcatattctt 4320
 25 atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggaggg agagggtgac 4380
 gaacaccagg catttccagg ggctataatt tctgtgaagc tctagcttaa gaagaaactt tttttaaaaa 4500
 ttgttggttg ttcatagttt ttgttgaaag atactgattc taaaaaatag aaactacttc 4560
 gactgtttgg ggattctttt tctttattat aagcaccttt gttgaagctc aaaaaaaatg atgcctcttt 4620
 attttaattg tatattatc aattatagga gtatttatgt aactatctta tgcttcaaaa aacaaaagta 4680
 30 aaacttttagc aattatagga tgtgtatata atatatatat atacatatat atttatacac atacaattta 4740
 tttgtgtgca tttgtatata ttttatgaga ttttaaccag aacaaaaggc gataaacagg 4800
 tgttttcctg ttgaatgtat ttttatgaga aaattttttg aataacacaa aatctcattc 4860
 cattccatag cagtgttttt gatcacttac gtgagagtat gtatgtgtgt gtgtgtgtgt 4920
 35 tacctgcagt ttaattggaa agatgtgtgt gccttgagca gtcagcattg cacctgctat ggagaagggg 4980
 gtgtgtgctg ggcacgcac ctcattttgga tttgctttca gttggttttc aatttgctca 5040
 attcctttat taaaatcttc acattgatgg cagtctttat ctgcactcact aatcagctcc tggatttttt 5100
 ctggccagag acattgatgg gtttgaaaca actactggaa tattgtccac aataagctgg 5160
 tttttttttt tcaacaatg tagtatgcct caaatataac tgactgtata ctatagtggg aacttttcaa 5220
 aagtttggtg gcacttttat actaattaac ccatttggtg attgagtttt cttttaaaaa 5280
 40 tgcttggtgt gaaagacaca gatacccagt atgcttaacg tgaaaagaaa atgtgttctg 5340
 ttttgtaaaag gaactttcaa gtattgttgt aaataacttg acagaggttg ctgaacttta 5400
 aaaaaaatta atttattatt ataattgacct aatttattaa tctgaagatt aaccattttt 5460
 ttgtcttaga atatcaaaaa gaaaaagaaa aagggtgttct agctgtttgc atcaaaggaa 5520
 45 aaaaagattt attatcaagg ggcaatatat ttatcttttc caaaataaat ttgttaatga 5580
 tacattacaa aatatagatt acatcagcct gattagtata aattttgttg gtaattaatc 5640
 cattcctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttgctt tttgtttttt 5700
 caatcatggc catattatga aaatactaac aggatatagg acaaggtgta aattttttta 5760
 ttattatttt aaagatatga tttatcttga gtgctgtatc tattactctt ttactttggg 5820
 50 tctgtttgtg ctcttgtaaa agaaaaatat aatttctctga agaataaaat agatatatgg 5880
 cacttgaggt gcatcatagt tctacagttt gtttttgggt tcttcaaaaa agctgtaaga 5940
 gaattatctg caacttgatt cttggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000
 aaaaaaaaaa a

55 <210> 34a → 60
 <211> 1036
 <212> DNA
 <213> Human

60 <400> 34a

65 mylvagdrgl agcghllvsl lglillpars gtralvclpc deskceprn rpgsivqgvc 60
 gccytcasgg nescggtfgi ygtcdrglrc virpplngds lteyeagvce denwtddqll 120
 gfkpcnenli agcniingkc ecntirtcsn pfefpsqdmc lsalkrieee kpdcskarce 180
 vqfsprcped svliegyapp gecclplsrc vcnpagclrk vcqpgnlml vskasgkpgc 240

5 ccdlyeckpv fgvdcrvec ptvqqtacpp dsyetqvrllt adgcctlptr ceclsglclgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmfr mdncrfrcrcq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcwatvcgq tctnpvkvpq eccpvceep iitvdppacg elsncctltrk 480
 dcingfkrdh ngcrctcqc in tqelcserkq gctlncpfgr ltdaqnceic ecrprpkkr 540
 piicdkycpl gllknkhgcl icrckkcpel scskicplgf qqdshgcllc kreasasag 600
 ppilsgtclt vdghhkhknee shwdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfveg etwnidsctq ctchsgrvlc etevcppllc 720
 10 qnpsrtqdsc cpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkp d vctscicids 780
 viscfasesc svscerpvlr kgqccpycik dtipkkvvch fsgkayadee rwdldsc thc 840
 yclqggtlcs tvscpplpvc epinvegsc pmcpemyvpe ptnipiekt hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiliic lsiiiaflfi 960
 nqkkqwipll cwyrtpkps slnnqlvsvd ckkgtrvqv d ssqrmlriae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35

<211> 716

<212> DNA

20 <213> Human

<400> 35

25 gcagtagctg gagggtcctg caggggggaaa gcgaaccggg ccctgaagtc cgggggcagtc 60
 acccggggct cctggggccgc tctgccgggc tgggggtgag cagcgatcct gctttgtccc 120
 agaagtcag agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180
 ggaggctgag gaaggcatga agagtgaggc ccacctgctg gccgactgag aaaagaattt 240
 30 ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag aggacggggc 300
 ttgagggaat ctctgattc tcttatatg acctcaaaact gaccatacta aacagtgtag 360
 aagggtcttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420
 gtcagtggtg agtagacggg ttcctccacc cagggttgac tcagggggat gatctgggtc 480
 ccattctggg cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 35 tctggttagt gtcgtaacct ctgtgtgcct cccgttacc catctgtcca gtgagctcag 600
 cccccatcca cctaacaggg tggccacagg gattactgag ggttaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttcctt ccacatcaaa aaaaaa

<210> 36

<211> 395

<212> DNA

40 <213> Human

<400> 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcc tttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240
 gccagtaaaa accaaagtca gggtaaccaa tgtcatttta caaatgtta aaaccctaata 300
 50 tgcagttcct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37

<211> 134

<212> DNA

55 <213> Human

<400> 37

60 ccctcgagcg gccgcccggg caggtagctt taccaccgaa ttgttcactt gactttaaga 60
 aaccataaaa gctgcctggc tttcagcaac aggcctatca acaccatggg gactctccat 120
 aagggacacc gtgt

<210> 38

<211> 644

<212> DNA

65

<213> Human

<400> 38

5 aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
 cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
 gggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
 ggaatatttg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
 gcttggtgaa gttacgaaac ttgtccaaaa tcacacaaact tgtaaagggc acagccaaga 300
 10 ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaga 360
 aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
 ttcgcaccgg aaaatgtagc ttcccgggta agtaccttgg ccatgtagaa gttgatgaat 480
 caagagggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagtctt 540
 tcaaaggctt ctttgaaaaa actggaaaga aagcagttaa agcagtttct gtgggtctaa 600
 15 gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

<210> 39

<211> 657

<212> DNA

<213> Human

<400> 39

25 ctttttgttt gggttttcca atgtagatgt ctcagtgaat tgtgcagata tactttgttc 60
 cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcttggccca 120
 gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
 tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
 acctgtctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
 agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
 30 tgggtcctttg agcaaaatga gaagaaaaaa ttctgtctcag cagtattcac tgtgttaaga 420
 ttttttgttt tttacacgaa tggaaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480
 aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
 taagaaatc tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600
 atgtttgctt caatagaaat ttgttcccac ttgtattttc aacaaaatta tcggaac

<210> 40

<211> 1328

<212> DNA

<213> Human

40

<400> 40

acaattttta aataactagc aattaatcac agcatatcag gaaaaagtac acagtgaatt 60
 ctggttagtt tttgtaggct cattatgggt aggggtcgta agatgtatat aagaacctac 120
 45 ctatcatgct gtatgtatca ctcattccat tttcatgttc catgcatact cgggcatcat 180
 gctaataatgt atccttttta gcactctcaa ggaaacaaaa gggcctttta tttttataaa 240
 ggtaaaaaaa attcccaaaa tttttgcac tgaatgtacc aaagggtgaag ggacattaca 300
 atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
 50 acttcccttca cagtgccgtg tctaccacta caaggactgt gcatctaagt aataattttt 420
 ccatacatca aatactttac agtatgatag gcattttatt aaaatgcatt agactctctt 480
 gcttttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaaacac 600
 tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660
 actcagaact atattttctaa gcctgcattt tcaactgatgc ataattttct tagtaatat 720
 55 aagagacagt ttttctatgg catctccaaa actgcattgac atcactagtc ttacttctgc 780
 ttaattttat gagaaggat tcttcatttt aattgtcttt gggattactc cacatctctt 840
 tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaaagc 900
 attggattga catatggttt gccagcctat ggggtttacag gcattgcccc aacatttctt 960
 tgagatctat atttataagc agccatggaa ttcttattat gggatgttgg caatcttaca 1020
 60 ttttatagag gtcataatgca tagttttcat aggtgttttg taagaactga ttgctctctt 1080
 gtgagtttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttaccact 1140
 ctgcactaaa ggcacgtact gcagtggtgaa gaaatgttct taatagaaatc 1200
 tggaaaataa aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
 65 ttttaactgg aaatggttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
 tgaaaaaaa

<210> 41
 <211> 987
 <212> DNA
 <213> Human

5

<400> 41

10	aacagagact	ggcacaggac	ctcttcattg	caggaagatg	gtagtgtagg	caggtaacat	60
	tgagctcttt	tcaaaaaagg	agagctcttc	ttcaagataa	ggaagtggta	gttatggtagg	120
	taacccccgg	ctatcagtc	ggatgggttc	cacccctcct	gctgtaggat	ggaagcagcc	180
	atggagtg	agggagggc	aataagacac	ccctccacag	agcttgccat	catgggaagc	240
	tggttctacc	tcttcctggc	tcctttgttt	aaaggcctgg	ctgggagcct	tccttttggg	300
	tgtctttctc	ttctccaacc	aacagaaaag	actgctcttc	aaagggtggag	ggcttctcatg	360
15	aaacacagct	gccaggagcc	caggcacagg	gctggggggc	tggaataagg	agggcacaca	420
	ggaggaggga	ggagctggta	gggagatgct	ggctttacct	aaggtctcga	aacaaggagg	480
	gcagaatagg	cagaggcctc	tccgtccacg	gccccatttt	gacagatggc	gggacggaaa	540
	tgcaatagac	cagcctgcaa	gaaagacatg	tgttttgatg	acaggcagtg	tgccggggtg	600
	gaacaagcac	aggccttgga	atccaatgga	ctgaatcaga	accctaggcc	tgccatctgt	660
20	cagccgggtg	acctgggtca	attttagcct	ctaaaagcct	cagtctcctt	atctgcaaaa	720
	tgaggcttgt	gatacctgtt	ttgaagggtt	gctgagaaaa	ttaaagataa	gggtatccaa	780
	aatagtctac	ggccatacca	ccctgaacgt	gcctaatactc	gtaagctaag	cagggtcagg	840
	cctggttagt	acctggatgg	ggagagtatg	gaaaacatac	ctgcccgcag	ttggagttgg	900
	actctgtctt	aacagtagcg	tggcacacag	aaggcactca	gtaaataactt	gttgaataaa	960
25	tgaagtagcg	atttggtgtg	aaaaaaa				

<210> 42
 <211> 956
 <212> DNA
 <213> Human

30

<400> 42

35	cggacgggtg	ggcggacgcg	tgggtgcagg	agcagggcgg	ctgccgactg	ccccaaccaa	60
	ggaaggagcc	cctgagtc	cctgcgcctc	catccatctg	tccggccaga	gccggcatcc	120
	ttgcctgtct	aaagccttaa	ctaagactcc	cgccccgggc	tgccctgtg	cagaccttac	180
	tcaggggatg	tttacctggg	gctcgggaag	ggaggggaag	gggcccggga	gggggcacgg	240
	cagggcgtgtg	gcagccacac	gcaggcggcc	agggcggcca	gggacccaaa	gcaggatgac	300
	cacgcacctc	cacgccactg	cctccccga	atgcattttg	aaccaaagtc	taaactgagc	360
40	tcgcagcccc	cgcgcctcc	ctccgcctcc	catcccgtct	agcgtctg	acagatggac	420
	gcaggccctg	tccagcccc	agtgcgtctg	ttccgggtcc	cacagactgc	cccagccaac	480
	gagattgtctg	gaaaccaagt	caggccagg	gggcggacaa	aaggggccagg	tgccggcctg	540
	gggggaacga	tgctccgagg	actggactgt	ttttttcaca	catcggtg	gcagcgggtg	600
	gaaggaaaag	cagatgtaaa	tgatgtgttg	gttttacagg	tatatatttt	ataccttcaa	660
45	tgaattaat	cagatgtttt	acgcaaggaa	ggacttacct	agtattactg	ctgctgtgct	720
	tttgatctct	gcttaccgtt	caagaggcgt	gtgcaggccg	acagtcgggtg	accccatcac	780
	tcgcaggacc	aagggggcgg	ggactgctgg	ctcacgcccc	gctgtgtcct	ccctccctc	840
	ccttccttgg	gcagaatgaa	ttcgatgcgt	attctgtggc	cgccatctgc	gcagggtggt	900
	ggtattctgt	catttacaca	cgtcgttcta	attaaaaagc	gaattatact	ccaaaa	

50

<210> 43
 <211> 536
 <212> DNA
 <213> Human

55

<400> 43

60	aaataaacac	ttccataaca	ttttgttttc	gaagtctatt	aatgcaatcc	cacttttttc	60
	cccctagttt	ctaaatgtta	aagagagggg	aaaaaaggct	caggatagtt	ttcacctcac	120
	agtgttagct	gtcttttatt	ttactcttgg	aaatagagac	tccattaggg	ttttgacatt	180
	ttgggaaccc	agttttacca	ttgtgtcagt	aaaacaataa	gatagtttga	gacatatga	240
	tctaaataaa	gacatttgaa	gggttagttt	gaatttctaaa	agtaggtaat	agccaaatag	300
	cattctcatc	ccttaacaga	caaaaaactta	tttgtcaaaa	gaattagaaa	aggtgaaaat	360
	attttttcca	gatgaaactt	gtgccacttc	caattgacta	atgaaataca	aggagacaga	420
65	ctggaaaaag	tgggttatgc	cacctttaaa	accctttctg	gtaaatatta	tggtagctaa	480
	aggggtggtt	ccccggcacc	tggacctgga	caggtagggg	tccgtgggta	accagt	

<210> 44
 <211> 1630
 <212> DNA
 <213> Human

5

<400> 44

10	ggggagggac	gagtatggaa	ccctgaaggt	agcaagtcca	ggcactggcc	tgaccatccg	60
	gctccctggg	caccaagtcc	caggcaggag	cagctgtttt	ccatcccttc	ccagacaagc	120
	tctattttta	tcacaatgac	ctttagagag	gtctcccagg	ccagctcaag	gtgtcccact	180
	atccccctctg	gaggggaagag	gcaggaaaaat	tctccccggg	tccctgtcat	gctactttct	240
	ccatcccaggt	tcagactgtc	caggacatct	tatctgcagc	cataagagaa	ttataaggca	300
	gtgatttccc	ttaggcccag	gacttgggccc	tccagctcat	ctgttccttc	tgggcccatt	360
15	catggcaggt	tctgggctca	aagctgaact	ggggagagaa	gagatacaga	gctaccatgt	420
	gactttacct	gattgccctc	agtttggggg	tgcttattgg	gaaagagaga	gacaaagagt	480
	tacttggttac	gggaaatatg	aaaagcatgg	ccaggatgca	tagaggagat	tctagcaggg	540
	gacaggattg	gctcagatga	cccctgaggg	ctcttccagt	cttgaaatgc	attccatgat	600
	attaggaagt	cgggggtggg	tggtggtggg	gggctagtgt	ggtttgaatt	tagggggccga	660
20	tgagcttggg	tacgtgagca	gggtgttaag	ttagggtctg	cctgtatttc	tggtcccctt	720
	ggaaatgtcc	ccttcttcag	tgtcagacct	cagtcccagt	gtccatatcg	tgcccagaaa	780
	agtagacatt	atcctgcccc	atcccttccc	cagtgcactc	tgacctagct	agtgcctggg	840
	gcccagtgac	ctgggggagc	ctggctgcag	gccctcactg	gttccctaaa	ccttgggtggc	900
	tgtgattcag	gtccccaggg	gggactcagg	gaggaatatg	gctgagttct	gtagtttcca	960
25	gagttggctg	gtagagcctt	ctagaggttc	agaatattag	cttcaggatc	agctgggggt	1020
	atggaattgg	ctgaggatca	aacgtatgta	ggtgaaagga	taccaggatg	ttgctaaagg	1080
	tgagggacag	tttgggtttg	ggacttacca	gggtgatgtt	agatctggaa	cccccaagtg	1140
	aggctggagg	gagttaaggt	cagtatggaa	gatagggttg	ggacagggtg	ctttggaatg	1200
	aaagagtgac	cttagagggc	tccttggggc	tcaggaatgc	tcctgctgct	gtgaagatga	1260
30	gaaggtgctc	ttactcagtt	aatgatgagt	gactatat	accaaagccc	ctacctgctg	1320
	ctgggtccct	tgtagcacag	gagactgggg	ctaaggggccc	ctcccaggga	agggacacca	1380
	tcaggccctc	ggctgaggca	gtagcataga	ggatccattt	ctacctgcat	ttcccagagg	1440
	actagcagga	ggcagccttg	agaaaccggc	agttcccaag	ccagcgcttg	gctgttctct	1500
	cattgtcact	gccctctccc	caacctctcc	tctaaccac	tagagattgc	ctgtgtcctg	1560
35	cctcttgcct	cttgtagaat	gcagctctgg	ccctcaataa	atgcttcctg	cattcatctg	1620
	caaaaaaaaa						

<210> 45
 <211> 169
 <212> DNA
 <213> Human

40

<400> 45

45	tcttttgctt	ttagcttttt	atttttgtat	taacaggagt	cttattacac	ataggtctga	60
	taaaactggg	ttatgatctt	cagtctgatt	ccagtgtctg	ataactagat	aacgtatgaa	120
	ggaaaaacga	cgacgaacaa	aaaagtaagt	gcttggaaga	cttagttga		

<210> 46
 <211> 769
 <212> DNA
 <213> Human

50

<400> 46

55	tgcagggtcat	atttactatc	ggcaataaaaa	ggaagcaaaag	cagtattaag	cagcgggtgga	60
	atttgtcgct	ttcacttttt	ataaagtgtc	acataaaatg	tcataatttc	aaatttaaaa	120
	acataactcc	agttcttacc	atgagaacag	catgggtgatc	acgaaggatc	ttcttgaaaa	180
	aaacaaaaaac	aaaaacaaaa	aacaatgatc	tcttctgggt	atcacatcaa	atgagataca	240
	aagggtgtact	aggcaatctt	agagatctgg	caacttattt	tatatataag	gcactctgtga	300
60	ccaagagacg	ttatgaatta	aatgtacaaa	tgtattatgt	ataaatgtat	taaatgcaag	360
	cttcataata	tgacaccaat	gtctctaagt	tgctcagaga	tcttgactgg	ctgtggccct	420
	ggccagctcc	tttcttgata	gtctgattct	gccttcatat	ataggcagct	cctgtatcatc	480
	catgccagtg	aatgagaaaa	caagcatgga	atatataaac	tttaacatta	aaaaatgttt	540
	tattttgtaa	taaaatcaaa	tttcccattg	aaaccttcaa	aaactttgca	gaatgaggtt	600
65	ttgatataatg	tgtacaagta	gtaccttctt	agtgcaagaa	aacatcatta	tttctgtctg	660
	cctgcctttt	tgttttttaa	aatgaagact	atcattgaaa	caagtttgtc	ttcagtatca	720

ggacatgttg acggagagga aaggtaggaa agggttaggg atagaagcc

<210> 47

<211> 2529

5 <212> DNA

<213> Human

<400> 47

10	tttagttcat	agtaatgtaa	aaccatttgt	ttaattctaa	atcaaatac	tttcacaaca	60
	gtgaaaatta	gtgactgggt	aagggtgtgcc	actgtacata	tcatcatttt	ctgactgggg	120
	tcaggacctg	gtcctagtcc	acaaggggtg	caggaggagg	gtggaggcta	agaacacaga	180
	aaacacacaa	aagaaaggaa	agctgccttg	gcagaaggat	gaggtgggtga	gcttgccgag	240
15	ggatgggtggg	aagggggctc	cctgttgggg	ccgagccagg	agtcccaagt	cagctctcct	300
	gccttactta	gctcctggca	gaggggtgagt	ggggacctac	gaggttcaaa	atcaaattggc	360
	atlttgccag	cctggcttta	ctaacagggt	cccagagtgc	ctctgttggc	tgagctctcc	420
	tgggctcact	ccatttcatt	gaagagtcca	aatgattcat	tttcctaccc	acaacttttc	480
	attattcttc	tggaaaccca	tttctgttga	gtccatctga	cttaagtcct	ctctccctcc	540
20	actagttggg	gccactgcac	tgaggggggt	cccaccaatt	ctctctagag	aagagacact	600
	ccagaggccc	ctgcaacttt	gcggatttcc	agaagggtgat	aaaaagagca	ctcttgagtg	660
	gggtgccagg	aatgtttaaa	atctatcagg	cacactataa	agctgggtgt	ttcttcctac	720
	caagtggatt	cggcatatga	accacctact	caatacttta	tattttgtct	gtttaaacac	780
	tgaactctgg	tgttgacagg	tacaaaggag	aagagatggg	gactgtgaag	aggggagggc	840
25	ttccctcatc	ttcctcaaga	tctttgtttc	cataaactat	gcagtcataa	ttgagaaaaa	900
	gcaatagatg	gggcttccta	ccatttgttg	gttattgtctg	gggttagcca	ggagcagtgt	960
	ggatggcaaa	gtaggagaga	ggcccagagg	aaagcccata	tcctccagc	tttgggggtct	1020
	ccagaaagag	gctggatttc	tgggatgaag	cctagaaggc	agagcaagaa	ctgttccacc	1080
	aggtgaacag	tccatcctgc	ttggtacat	agtcctcaa	taagattcag	aggaagaagc	1140
30	ttatgaaact	gaaaatcaaa	tcaagggtatt	gggaagaata	atttccctc	gattccacag	1200
	gaggggaagac	cacacaatat	cattgtgctg	gggtcccca	aggccctgcc	acctggcttt	1260
	acaaatcatc	aggggttgcc	tgcttggcag	tcacatgctt	ccctggtttt	agcacacata	1320
	caaggagttt	tcagggaact	ctatcaagcc	ataccaaaat	cagggtcaca	tgtgggtttc	1380
	ccctttcctt	gcctcttcct	aaaagacaac	ttggcttctg	aggatgggtg	tcttttgcac	1440
35	gcagttgggc	tgacctgaça	aagccccag	tttctgtgg	caggttctgg	gagaggatgc	1500
	attcaagctt	ctgcagccta	ggggacaggg	ctgcttgttc	agttattact	gcctcggagc	1560
	tccaaatccc	accaaagtcc	tgactccagg	tctttcctaa	tgacacagtag	tcagtcctcag	1620
	cttcggcagt	attctcggct	gtatgttctc	tggcagagag	aggcagatga	acatagtttt	1680
	agggagaaa	ctgatgggaa	acctgtgagt	taagccacat	gtctcaccag	gaataattta	1740
40	tgccaggaaa	ccagggaagtc	attcaagttg	ttctctgagg	ccaaagacac	tgagcacagc	1800
	ccagagccaa	taaaagatct	ttgagtctct	ggtgaattca	cgaagtgacc	ccagcttttag	1860
	ctactgcaat	tatgattttt	atgggacagc	aatttcttgc	atctctacag	aggaagaaga	1920
	gggggagtgg	gaggggaagg	aaagagaaca	gagcggcact	gggatttgaa	aggggaacct	1980
	ctctatctga	ggagccccc	ctggcttcag	aagcaactta	ccaaggggta	tttaaagaca	2040
45	tgaaaatttc	cagaaatacc	atlttggtgca	tccttttgtt	tctgtaatat	taaactcagg	2100
	tgaattata	ctctgacagt	ttctctctt	ctgcctcttc	cctctgcaga	gtcaggacct	2160
	gcagaactgg	ctgaacaag	atlttcattgt	gtcaccatg	agagatgact	caatggcaag	2220
	gcctgaagtt	atagagtgtt	tacagcgggtg	gcgatattca	gggtcatcg	ccaactggct	2280
	tcgagttcca	aagctctgat	gaagaaacaa	gactccttga	tgtgttactg	atcccactga	2340
50	ttccaggagt	caagattagc	caggaagcca	aacaccagga	gttgggggtg	cacgtcacca	2400
	gtccagagcc	ctgccacgga	tgtacgcagg	agcccagcat	taggcaatca	ggagccagaa	2460
	catgatcacc	agggccacaa	ataggaagag	gcgtgacagg	aactgctcgt	ccacatacct	2520
	gggggtgtcc						

<210> 48

<211> 1553

<212> DNA

<213> Human

<400> 48

60	tttttttttt	tttttgattt	ctgggacaat	taagctttat	ttttcatata	tatatatatt	60
	ttcatatata	tatatacata	catatatata	ggaacaatt	tgcaaattta	cacacctgac	120
	aaaaccatat	atacacacat	atgtatgcac	acacacagac	agacacacac	acccgaagct	180
65	ctagccaggc	ccgtttttcca	tccttaagta	ccattctctc	atttgggccc	ttctagggtt	240
	ggggccctga	gcttggtttg	tagaagtttg	gtgctaatat	aaccatagct	ttaatcccca	300
	tgaaggacag	tgtagacctc	atctttgtct	gtcctccgct	gcctttcagt	tttacgtgat	360

5 ccatcaagag ggctatggga gccaaagtga caccgggggat tgaggctaata tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttcctcga 480
 gacggagtct cgctgtgttg cccaggctgg agtgcagtgg cacggtctcg gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
 taggtgccaa ccactacgcc tagctaattt ttttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgtcctg acttttgtat ccgcccgcct cggcctccca 720
 aagtgtctggg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780
 atgacaccag ttcttggttt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 10 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggggtgctctc 900
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcagtgg tgcacctgga tgggtggaagc cagccttttg ggcaggaaac cagctcagag 1020
 aggctaccca gctcagctgc tggcaggagc caggatatta cagccataat gtgtgtaaag 1080
 aaaaaacacg ttctgcaaga aactctccta ccgctcggg agactggggc tccttgcttg 1140
 ggatgagctt cactcaacgt ggagatgggt gtggactggg cctgaaaaag cgggccttgc 1200
 15 agggccaagt gaggtcctca ggttcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
 cgaggggagc aggaggcttc tctctagtcc ctttgagggc tttggctgag agaagagtga 1320
 gcagggagct gggaatggtc caggcagggg agggagctga agtgattcgg ggctaattgcc 1380
 tcagatcgat gtatttctct ccctggtctc ccggagccct cttgtcaccg ctgctgcctt 1440
 20 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agtctgctct 1500
 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtgggtccc agctactcag gaggttgagg cgggaggatt gcttgagccc aggagttgga 60
 tgttgacagt agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120
 gtctcagaaa acaaaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180
 gcctgtcaga acacttggtt actcctaccc cagatcagtg gacctgggaa tgagggttg 240
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccatgggaac cctggccaca 300
 35 gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360
 ggaggggtgg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420
 tgcgtgcctg tgtgtgtgag tgccccctcc ctgcagccgt cgggtggtatc tccctccagc 480
 cccttcgcca ccttctgagc attgtctgtc cagctgagac tgcccagaga cagcagagct 540
 ccacgtgggt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600
 40 cagggtgctaa atgacccgac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660
 gtcccgtgta cctgcccccg tggcgtctca cgggtgatgc tgctcctgac attgggtgtc 720
 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780
 ttcaataaaa atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840
 tactttgacc tcttgacct aacccttcc ttgggtccga ggctggtagc tttgttact 900
 tcagatgggt gggggcgggt g

<210> 50

<211> 338

<212> DNA

50 <213> Human

<400> 50

55 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
 tcccttccag atattacccc atttctctac tttccattgt agccaaaact tccaaaaatt 120
 catgttctgt cttcatttcc tcatgttcaa cccacctgt cttagctacc accctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgatac cataactaat gatccttctg 240
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300
 gtaagaaact ttctttcttg aattcttggg tctcttgg

60 <210> 51

<211> 1191

<212> DNA

<213> Human

65 <400> 51

	ctagcaagca	ggtaaacgag	ctttgtacaa	acacacacag	accaacacat	ccgggggatgg	60
	ctgtgtgttg	ctagagcaga	ggctgattaa	acactcagtg	tggtggctct	ctgtgccact	120
	cctggaaaat	aatgaattgg	gtaaggaaca	gttaataaga	aaatgtgcct	tgctaactgt	180
5	gcacattaca	acaaagagct	ggcagctcct	gaaggaaaag	ggcttgtgcc	gctgccgttc	240
	aaacttgtca	gtcaactcat	gccagcagcc	tcagcgtctg	cctccccagc	acaccctcat	300
	tacatgtgtc	tgtctggcct	gatctgtgca	tcgtctcgga	gacgctcctg	acaagtctgg	360
	aatttctcta	tttctccact	ggtgcaaaga	gcggaattct	cctgcttct	cttctgtcac	420
	ccccgctcct	ctcccccagg	aggctccttg	atztatggta	gctttggact	tgcttccccg	480
10	tctgactgtc	cttgacttct	agaatggaag	aagctgagct	ggtgaaggga	agactccagg	540
	ccatcacaga	taaaagaaaa	atacaggaag	aaatctcaca	gaagcgtctg	aaaatagagg	600
	aagacaaact	aaagcaccag	catttgaaga	aaaaggcctt	gagggagaaa	tggcttctag	660
	atggaatcag	cagcggaaaa	gaacaggaag	agatgaagaa	gcaaaatcaa	caagaccagc	720
	accagatcca	ggttctagaa	caaagtatcc	tcaggcttga	gaaagagatc	caagatcctg	780
15	aaaaagctga	actgcaaatc	tcaacgaagg	aagaggccat	tttaaagaaa	ctaaagtcaa	840
	ttgagcggac	aacagaagac	attataagat	ctgtgaaagt	ggaaagagaa	gaaagagcag	900
	aagagtcaat	tgaggacatc	tatgctaata	tccctgacct	tccaaagtcc	tacatacctt	960
	ctaggttaag	gaaggagata	aatgaagaaa	aagaagatga	tgaacaaaat	aggaaagctt	1020
	tatatgccat	ggaaattaaa	gttgaaaaag	acttgaagac	tggagaaaag	acagttctgt	1080
20	cttccaatac	ctctggccat	cagatgacct	taaaagggtac	aggagtataa	gtttaagatg	1140
	atggggcaaaa	gtccagtgtg	ttcagtaaa	tgctaatacac	aagttggagg	t	

<210> 52

<211> 1200

<212> DNA

25 <213> Human

<400> 52

30	aacagggact	ctcactctat	caaccccagg	ctggagtcgg	gtgcgcccac	cctggctccc	60
	tgcaacctcc	gcctcccagg	ctcaagcaac	tctcctgcct	cagtcgctct	agtagctggg	120
	actacaggca	cacaccacca	tgcccagcca	atttttgcat	tttttgtaga	gacaggggtt	180
	cgccttctgt	ccaggccggc	atcatatact	ttaaatcatg	cccagatgac	tttaatacct	240
	aatacaatat	atcaggttgg	tttaaaaaata	attgcttttt	tattattttt	gcattttttg	300
35	accaacctta	atgctatgta	aatagttgtt	atactgttgc	ttaacaacag	tatgacaatt	360
	ttggcttttt	ctttgtatta	ttttgtattt	ttttttttta	ttgtgtggtc	tttttttttt	420
	ttctcagtg	tttcaattcc	tccttggttg	aatccatgga	tgcaaaaccc	acagatatga	480
	agggtggct	atatatgcat	tgatgattgt	cctattatat	tagttataaa	gtgtcattta	540
	atatgtagtg	aaagttatgg	tacagtggaa	agagtagttg	aaaacataaa	catttggacc	600
	tttcaagaaa	ggtagcttgg	tgaagttttt	caccttcaaa	ctatgtccca	gtcagggttc	660
40	tgctactaat	tagctataat	ctttgcacaa	attacatcac	ctttgagtct	cagttgcctc	720
	acctgtaaaa	tgaagaact	ggatactctc	taaggtcact	tccagccctg	tcattctata	780
	actctgttat	gctgaggaag	aaattcacat	tgtgttaact	gtatgagtca	aactgaaaaa	840
	gattattaaa	gtgggaaaaa	gccaatgtct	tctcttagaa	agctcaacta	aatttgagaa	900
	gaataatctt	ttcaattttt	taagaattta	aatattttta	agggtttgac	ctattttatt	960
45	agagatgggg	tctcactctg	tcacccagac	tggagtacag	tggcacaatc	atagctcact	1020
	gctgcctcaa	attcatgggc	tcaagtgatc	ctcctgcctc	tgccctccaga	gtagctgcga	1080
	ctatgggcat	gtgccaccac	gcctggctaa	catttgtatt	gacctattta	tttattgtga	1140
	tttatatctt	tttttttttt	tctttttttt	ttttttacaa	aatcagaaat	acttattttt	1200

<210> 53

<211> 989

<212> DNA

<213> Human

55 <400> 53

60	aagccaccac	tcaaaaacttc	ctatacattt	tcacagcaga	gacaagtga	cattttatttt	60
	tatgcctttc	ttcctatgtg	tatttcaagt	ctttttcaaa	acaaggcccc	aggactctcc	120
	gattcaatta	gtccttgggc	tggtcgactg	tgcaggagtc	cagggagcct	ctacaaatgc	180
	agagtgactc	tttaccaaca	taaaccctag	atacatgcaa	aaagcaggac	ccttctctca	240
	ggaatgtgcc	atttcagatg	cacagacccc	atgcagaaaa	gctggaattt	tccttggaac	300
	cgactgtgat	agaggtgctt	acatgaacat	tgctactgtc	tttctttttt	tttgagacag	360
	gtttcgcttg	tgcccaggct	gagtgcattg	cgtgatctca	ctcactgcaa	ttccacctcc	420
	aggttcaagc	attctcctgc	tcagcctcct	agtagctggg	ttacaggcac	tgccaccatg	480
65	ccggctaatt	ttgtattttt	gtagagatgg	atttctccat	ttggtcaggc	gggtctcgaa	540
	cccaacctca	gtgatctgac	acctcagcct	cctaagtgtt	ggattacagg	atgagccacc	600

cgaccggcca ctactgtctt tctttgaccc ttccagtttc gaagataaag aggaaataat 660
 ttctctgaag tacttgataa aattttccaaa caaacacat gtccacttca ctgataaaaad 720
 atttaccgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaaagag 780
 5 ttaagatttc ttcagcaaaa tagatgattc acatcttcaa gtcctttttg aaatcagtta 840
 ttaatatatt tctttcctca tttccatctg aatgactgca gcaatagttt tttttttttt 900
 tttttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtg cactggcgcaa 960
 gcccggtca cgcgaatctc tgccaccgcg

<210> 54
 10 <211> 250
 <212> DNA
 <213> Human

<400> 54

15 catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60
 gcagaggcta ctacaagaag tagggaatca agtccctcac atgggctatt aaaactaggt 120
 agtgggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180
 20 aaagggcatt ctttaggaac tgcattctgt aaccacacac ttgatccaag agctagggaa 240
 acttcagttg

<210> 55
 <211> 2270
 <212> DNA
 25 <213> Human

<400> 55

30 gcgccccga gcagcgcccg cgccctccgc gccttctccg ccgggacctc gagcgaaaga 60
 ggcccgcgcg ccgcccagcc ctgcctcccc tgcccaaccg gcacaccgcy ccgccacccc 120
 gaccccgctg cgcacggcct gtccgctgca caccagcttg ttggcgctct cgtcgccgcy 180
 ctgcgcccg gctactcctg cgcgccacaa tgagctcccg catcgccagg gcgctcgcc 240
 tagtcgtcac ccttctccac ttgaccaggc ttggcgctct cactgcccc gctgcctgcc 300
 35 actgccccct ggaggcgccc aagtgcgcgc cgggagtcgg gctggtccgg gacggctgcg 360
 gctgctgtaa ggtctgcgcc aagcagctca acgaggactg cagcaaaacg cagccctgcg 420
 accacaccaa ggggctggaa tgcaacttcg gcgccaaagc caccgctctg aaggggatct 480
 gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaacgggg 540
 aaagtttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600
 40 ttctctgtg tccccaagaa ctatctctcc ccaacttggg ctgtcccaac ctcgggctgg 660
 tcaaaagttac cgggcagtg cgcgaggagt gggctctgtg cgaggatagt atcaaggacc 720
 ccatggagga ccaggacggc ctccctggca aggagctggg attcgatgcc tccgaggtgg 780
 agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggtcc 840
 ctgtttttgg aatggagcct cgcattcctat acaacccttt acaaggccag aaatgtattg 900
 45 ttcaaacaaac ttcatggtcc cagtgtctca agacctgtgg aactgggtatc tccacacgag 960
 ttaccaatga caaccctgag tgccgccttg tgaaagaaac ccgattttgt gaggtgcggc 1020
 cttgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagacgaaga 1080
 aatccccga accagtcagg ttactttacg ctggatgttt gagtgtgaag aaataccggc 1140
 ccaagtactg cggttcctgc gtggacggcc gatgctgcac gccccagctg accaggactg 1200
 50 tgaagatgcg gttccgctgc gaagatgggg agacattttc caagaacgct atgatgatcc 1260
 agtccctgcaa atgcaactac aactgccccg atgccaatga agcagcgttt cccttctaca 1320
 ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380
 cctagacaaa caaggagaaa gagtgtcaga atcagaatca tggagaaaat gggcgggggg 1440
 ggtgtgggtg atgggactca ttgtagaaag gaagccttgc tcattcttga ggagcattaa 1500
 55 ggtatttcga aactgccaa ggtgctggtg cggatggaca ctaatgcagc cagcattgaa 1560
 gaatactttg cttcatagta ttggagcaca tgttactgct tcatttttga gcttgtggag 1620
 ttgatgactt tctgttttct gtttgtaaat tatttgctaa gcatattttc tctaggcttt 1680
 ttctctttg ggttctaca gtcgtaaaaag agataataag attagttgga cagtttaaaag 1740
 cttttattcg tcctttgaca aaagtaaatg ggagggcatt ccattccctc ctgaaggggg 1800
 60 acactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860
 ggtgttttaa gactgaatgt tttattttatc aaaatgtagc ttttggggag ggaggggaaa 1920
 tgtaatactg gaataatttg taaatgattt taattttata ttcagtgaag agattttatt 1980
 tatggaatta accatttaat aaagaaatat ttacctaat tctgagtgtg tgccattcgg 2040
 tattttttaga ggtgctccaa agtcattagg aacaacctag ctcacgtact caattattca 2100
 aacaggactt attgggatac agcagtgatg taagctatta aaataagata atgattgctt 2160
 65 ttataccttc agtagagaaa agtcttttgc tataaagtaa tgtttaaaaa acatgtattg 2220
 aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

<210> 56
 <211> 1636
 <212> DNA
 <213> Human

5

<400> 56

10	cttgaatgaa	gctgacacca	agaaccgcgg	gaagagcttg	ggcccaaagc	aggaaaggga	60
	agcgctcgag	ttggaaagga	accgctgctg	ctggccgaac	tcaagcccgg	gcgc'ccccac	120
	cagtttgatt	ggaagtccag	ctgtgaaacc	tggagcgtcg	ccttctcccc	agatggctcc	180
	tggtttgctt	ggtctcaagg	acactgcatc	gtcaaactga	tcccctggcc	gttggaggag	240
	cagttcatcc	ctaaaggggt	tgaagccaaa	agccgaagta	gcaaaaatga	gacgaaaggg	300
	cggggcagcc	caaaagagaa	gacgctggac	tgtggtcaga	ttgtctgggg	gctggccttc	360
15	agcccgtggc	cttccccacc	cagcaggaag	ctctgggcac	gccaccaccc	ccaagtgcc	420
	gatgtctctt	gcctgggtct	tgtctacggg	ctcaacgatg	ggcagatcaa	gatctgggag	480
	gtgcagacag	ggctcctgct	tttgaatctt	tccggccacc	aagatgtcgt	gagagatctg	540
	agcttcacac	ccagtggcag	tttgattttg	gtctccgcgt	cacgggataa	gactcttcgc	600
	atctgggacc	tgaataaaca	cggtaaacag	attcaagtgt	tatcgggcca	cctgcagtgg	660
20	gtttactgct	gttccatctc	cccagactgc	agcatgctgt	gctctgcagc	tggagagaag	720
	tcgggtctttc	tatggagcat	gaggtcctac	acgttaattc	ggaagctaga	gggccatcaa	780
	agcagtgttg	tctcttgtga	cttctcccc	gactctgccc	tgcttgtcac	ggcttcttac	840
	gataccaatg	tgattatgtg	ggacccctac	accggcgaaa	ggctgaggtc	actccaccac	900
	acccagggtg	accccgccat	ggatgacagt	gacgtccaca	ttagctcact	gagatctgtg	960
25	tgcttctctc	cagaaggctt	gtaccttgcc	acggtggcag	atgacagact	cctcaggatc	1020
	tgggcccctgg	aactgaaaac	tcccattgca	tttgctccta	tgaccaatgg	gctttgctgc	1080
	acattttttc	cacatggtgg	agtcattgcc	acagggacaa	gagatggcca	cgtccagttc	1140
	tggacagctc	ctaggggtcct	gtcctcactg	aagcacttat	gccggaaagc	ccttcgaagt	1200
	ttcctaacaa	cttaccacag	cctagcactg	ccaatcccca	agaaaatgaa	agagttcctc	1260
30	acatacagga	ctttttaagc	aacaccacat	cttgtgtctc	tttgtagcag	ggtaaactcg	1320
	cctgtcaaaag	ggagttgctg	gaataatggg	ccaaacatct	ggtcttgcat	tgaaatagca	1380
	tttcttttggg	attgtgaata	gaatgtagca	aaaccagatt	ccagtgtaca	taaaagaatt	1440
	tttttgtctt	taaatagata	caaatgtcta	tcaactttaa	tcaagttgta	acttatattg	1500
	aagacaattt	gatacataat	aaaaaattat	gacaatgtcc	tgggaaaaaa	aaaatgtaga	1560
35	aagatggtga	agggtgggat	ggatgaggag	cgtggtgacg	ggggcctgca	gcgggttggg	1620
	gaccctgtgc	tgcgtt					

<210> 57
 <211> 460
 <212> DNA
 <213> Human

40

<400> 57

45	ccatgtgtgt	atgagagaga	gagagattgg	gagggagagg	gagctcacta	gcgcataatgt	60
	gcctccaggg	ggctgcagat	gtgtctgagg	gtgagcctgg	tgaagagaga	gacaaaagaa	120
	tggaaatgagc	taaagcagcc	gcctgggggtg	ggaggccgag	cccatttgta	tgcagcaggg	180
	ggcaggagcc	cagcaaggga	gcctccattc	ccaggactct	ggaggagagc	gagaccatcc	240
	atgcccgag	agccctccct	cacactccat	cctgtccagc	cctaattgtg	caggtgggga	300
50	aactgaggct	gggaagtcac	atagcaagtg	actggcagag	ctgggactgg	aacccaacca	360
	gcctcctaga	ccacggttct	tcccatcaat	ggaatgctag	agactccagc	caggtgggta	420
	ccgagctcga	attcgtaatc	atgggtcatag	ctgtttcctg			

<210> 58
 <211> 1049
 <212> DNA
 <213> Human

55

<400> 58

60	atctgatcaa	gaatacctgc	cctgggtcact	ctgcggatgt	ttctgtccac	ttgttcacat	60
	tgaggaccaa	gatatccttt	tttacagagg	cacttggtcg	gtctaacaca	gacacctcca	120
	tgacgacatg	ctggctcaca	ttttgcagtt	ctgcagaagt	ccccctccca	gcctggacta	180
	cagcagcact	ttcccgtggg	ggtgcagtag	ccgtttcgac	agagcctgga	gcactctgaa	240
65	gtcagtgtct	gtgcaggttg	taccgtggct	ctgcattcct	caggcattaa	aggtcttttg	300
	ggatctacaa	ttttgtagag	ttttccattg	tgagtctggg	tcatactttt	actgcttgat	360

```

5   aaaatgtaaa cttcacctag ttcattcttct ccaaatecca agatgtgacc ggaaaagtag 420
    cctctacagg acccactagt gccgacacag agtggttttt cttgccactg ctttgtcaca 480
    ggacttttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
    aatctttctg actggcagcc ccggtataca aatccacca ccaaaggacc attactgaat 600
    ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccccttat tatctgtaga 660
    attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
    tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
    aacacttcgg ggggctggtt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
10  ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
    aacccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
    aaaaacccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020
    acttcaagaa agactctggc tgttctcaa

15  <210> 59
    <211> 747
    <212> DNA
    <213> Human

20  <400> 59

25  tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
    ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
    cttaaataata atgtatcata ccaacccaag taaaccaagt acaaaaaata ttcatataaa 180
    gttgttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
30  atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
    ctctgtctgtc ccacacaaat gttaagaag tctactgcaat gtactccccg gctctgatga 360
    aaagaagccc ctggcacaaa agattccagt gccctgaag aggctccctt cctcctgtgg 420
    gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
    ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
    ccaattcaat gccacaccta ctggttacct tttgagggca tttctccaga cagaagcccc 600
    ttgaagccta ggtagggcag gatcagagat acaccctgtt ttgtctcgaa gggctccaca 660
    gcccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
    cgcgaaatta gtagtaatat cggccgc

```